DE3483094D1 - Kovalent gebundener komplex eines alpha-1-proteinase inhibitors mit einem wasserloeslichen polymer. - Google Patents

Kovalent gebundener komplex eines alpha-1-proteinase inhibitors mit einem wasserloeslichen polymer.

Info

Publication number
DE3483094D1
DE3483094D1 DE8484115620T DE3483094T DE3483094D1 DE 3483094 D1 DE3483094 D1 DE 3483094D1 DE 8484115620 T DE8484115620 T DE 8484115620T DE 3483094 T DE3483094 T DE 3483094T DE 3483094 D1 DE3483094 D1 DE 3483094D1
Authority
DE
Germany
Prior art keywords
soluble polymer
proteinase inhibitor
alpha
water
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8484115620T
Other languages
English (en)
Inventor
Gautam Mitra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Miles Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc filed Critical Miles Inc
Application granted granted Critical
Publication of DE3483094D1 publication Critical patent/DE3483094D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0023—Heat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C07K17/06—Peptides being immobilised on, or in, an organic carrier attached to the carrier via a bridging agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE8484115620T 1983-12-27 1984-12-17 Kovalent gebundener komplex eines alpha-1-proteinase inhibitors mit einem wasserloeslichen polymer. Expired - Lifetime DE3483094D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/565,810 US4496689A (en) 1983-12-27 1983-12-27 Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer

Publications (1)

Publication Number Publication Date
DE3483094D1 true DE3483094D1 (de) 1990-10-04

Family

ID=24260195

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8484115620T Expired - Lifetime DE3483094D1 (de) 1983-12-27 1984-12-17 Kovalent gebundener komplex eines alpha-1-proteinase inhibitors mit einem wasserloeslichen polymer.

Country Status (7)

Country Link
US (1) US4496689A (de)
EP (1) EP0147761B1 (de)
JP (1) JPH0696541B2 (de)
AT (1) ATE56025T1 (de)
CA (1) CA1242664A (de)
DE (1) DE3483094D1 (de)
ES (1) ES8605826A1 (de)

Families Citing this family (882)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3440988A1 (de) * 1984-11-09 1986-07-10 Hoechst Ag, 6230 Frankfurt Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4970300A (en) * 1985-02-01 1990-11-13 New York University Modified factor VIII
US4713240A (en) * 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5206344A (en) * 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4745180A (en) * 1986-06-27 1988-05-17 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using heparin fragments
US4894226A (en) * 1986-11-14 1990-01-16 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polyproline conjugation
FR2610633B1 (fr) * 1987-02-05 1992-09-18 Lille Transfusion Sanguine Procede d'obtention d'un concentre d'a 1-antitrypsine a partir de plasma humain et son utilisation a titre de medicament
US4847325A (en) * 1988-01-20 1989-07-11 Cetus Corporation Conjugation of polymer to colony stimulating factor-1
JP2761881B2 (ja) * 1988-03-10 1998-06-04 チッソ株式会社 抗体を固定化したアフイニテイクロマトグラフイ用担体
WO1990002558A1 (en) * 1988-09-09 1990-03-22 University Of Kentucky Research Foundation Elastase inhibiting polymers and methods
US5162307A (en) * 1988-09-09 1992-11-10 Board Of Trustees Of The University Of Kentucky Polymer bound elastase inhibitors
US5264214A (en) * 1988-11-21 1993-11-23 Collagen Corporation Composition for bone repair
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
JP2896580B2 (ja) * 1989-08-25 1999-05-31 チッソ株式会社 アミロース―リゾチームハイブリッドと活性化糖およびその製造法
US5179080A (en) * 1989-08-31 1993-01-12 Clinical Homecare, Corp. Formulations containing growth hormone and nutritional supplements, and methods of treating malnutrition in chronic lung disease
JP2978187B2 (ja) * 1989-11-02 1999-11-15 日本ケミカルリサーチ株式会社 修飾スーパーオキサイドディスムターゼの製造法
ES2063326T3 (es) * 1989-11-15 1995-01-01 Sandoz Ltd Conjugados de polimixina.
US5177059A (en) * 1989-11-15 1993-01-05 Sandoz Ltd. Polymyxin B conjugates
AU7681091A (en) * 1990-04-05 1991-10-30 John R Hoidal Method and medicament for prevention or medication of human leucocyte elastase-mediated pulmonary diseases
US5232984A (en) * 1990-10-15 1993-08-03 The Board Of The Regents The University Of Texas Biocompatible microcapsules
US5595732A (en) * 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
WO1992018141A1 (en) * 1991-04-18 1992-10-29 The Uab Research Foundation Compositions and methods for inhibiting elastase
US5284934A (en) * 1991-04-24 1994-02-08 Health Research Inc. Synthesis and utilization of carbohydrate-binding polymer-lectin conjugates
US5169627A (en) * 1991-10-28 1992-12-08 Mount Sinai School Of Medicine Of The City University Of New York Oral pharmaceutical composition containing a polyethylene glycol-immunoglobulin G conjugate for reconstitution of secretory immunity and method of reconstituting secretory immunity
WO1994001483A1 (en) * 1992-07-02 1994-01-20 Collagen Corporation Biocompatible polymer conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
US5981719A (en) * 1993-03-09 1999-11-09 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5554730A (en) * 1993-03-09 1996-09-10 Middlesex Sciences, Inc. Method and kit for making a polysaccharide-protein conjugate
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US5514665A (en) * 1993-12-30 1996-05-07 University Of British Columbia Method of preventing or reducing the risk of infection by bacterial pathogens utilizing simple and conjugated dextrans
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
DE4423131A1 (de) * 1994-07-01 1996-01-04 Bayer Ag Neue hIL-4-Mutantenproteine als Antagonisten oder partielle Agonisten des humanen Interleukin 4
US5545553A (en) * 1994-09-26 1996-08-13 The Rockefeller University Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
DE69637473T2 (de) 1995-06-07 2009-05-07 Glaxo Group Ltd., Greenford An einem thrombopoietin rezeptor bindende peptide und zusammensetzungen
US7883693B2 (en) * 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
EP0876165B1 (de) * 1995-12-18 2006-06-21 Angiotech BioMaterials Corp. Vernetzten polymerisatmassen und verfahren für ihre verwendung
US6833408B2 (en) * 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
US20050089958A1 (en) * 1996-01-09 2005-04-28 Genentech, Inc. Apo-2 ligand
US6998116B1 (en) * 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6046048A (en) * 1996-01-09 2000-04-04 Genetech, Inc. Apo-2 ligand
US20020165157A1 (en) * 1996-04-01 2002-11-07 Genentech, Inc. Apo-2LI and Apo-3 polypeptides
JP2000507829A (ja) * 1996-04-01 2000-06-27 ジェネンテック インコーポレーテッド Ａｐｏ―２ｌｉおよびａｐｏ―３アポトーシスポリペプチド
US7091311B2 (en) * 1996-06-07 2006-08-15 Smithkline Beecham Corporation Peptides and compounds that bind to a receptor
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6462176B1 (en) * 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US6072040A (en) * 1996-10-15 2000-06-06 Medical Analysis Systems, Inc. Stabilized conjugates of uncomplexed subunits of multimeric proteins
US20040241645A1 (en) * 1997-01-31 2004-12-02 Genentech, Inc. O-fucosyltransferase
EP0942992B1 (de) 1997-01-31 2007-03-07 Genentech, Inc. O-fukosyltransferase
WO1999021999A2 (en) 1997-10-29 1999-05-06 Genentech, Inc. Wnt-1 inducible genes
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
ES2361267T3 (es) 1997-04-07 2011-06-15 Genentech Inc. Procedimiento para la produccion de anticuerpos humanizados mediante mutagénesis aleatoria.
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
US6342369B1 (en) * 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
EP0981618B2 (de) 1997-05-15 2011-08-24 Genentech, Inc. Anti-apo-2 antikörper
US20100152426A1 (en) * 1997-05-15 2010-06-17 Ashkenazi Avi J Apo-2 receptor fusion proteins
JP2001523977A (ja) 1997-06-05 2001-11-27 ザ ユニバーシティ オブ テキサス システム ボード オブ リージェンツ Ａｐａｆ−１、ｃｅｄ−４ヒト相同体、カスパーゼ−３の活性化因子
DE69833487T9 (de) * 1997-06-12 2007-03-01 Innovata Plc, Ruddington Polymer-wirkstoff-konjugate zur behandlung von krebs
IL133122A0 (en) * 1997-06-18 2001-03-19 Genentech Inc Apo-2dcr polypeptides
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US20030175856A1 (en) * 1997-08-26 2003-09-18 Genetech, Inc. Rtd receptor
DE69841176D1 (en) * 1997-08-26 2009-11-05 Genentech Inc Rtd receptor
CA2382506A1 (en) 1997-09-17 1999-03-25 Genentech, Inc. Novel polypeptides and nucleic acids encoding pro293 which are useful for treating disorders of the pancreas
JP4303883B2 (ja) * 1997-09-18 2009-07-29 ジェネンテック・インコーポレーテッド ＤｃＲ３ポリペプチドというＴＮＦＲ相同体
US20040231011A1 (en) * 2001-06-28 2004-11-18 Genentech, Inc. DcR3 polypeptide, a TNFR homolog
JP2001522584A (ja) 1997-10-10 2001-11-20 ジェネンテク・インコーポレイテッド Ａｐｏ−３リガンドポリペプチド
US6387657B1 (en) 1997-10-29 2002-05-14 Genentech, Inc. WISP polypeptides and nucleic acids encoding same
DE69837897T2 (de) 1997-11-21 2008-03-06 Genentech Inc., San Francisco Mit A33 verwandte Antigene und deren pharmazeutische Verwendungen
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
AU2325199A (en) 1998-01-15 1999-08-02 Genentech Inc. Apo-2 ligand
EP2050762A3 (de) 1998-03-10 2009-07-08 Genentech, Inc. Neue Polypeptide und für diese kodierende Nukleinsäuren
ES2389387T3 (es) 1998-03-17 2012-10-25 Genentech, Inc. Polipéptidos homólogos de VEGF y de BMP1
EP1865061A3 (de) 1998-05-15 2007-12-19 Genentech, Inc. IL-17-homologe Polypeptide und ihre therapeutische Verwendung
DE69936382T3 (de) 1998-05-15 2011-07-07 Genentech, Inc., Calif. Therapeutische verwendungen von il-17 homologe polypeptide
AU4561199A (en) * 1998-06-12 1999-12-30 Genentech Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
DE69934425T2 (de) * 1998-10-23 2007-09-27 Amgen Inc., Thousand Oaks Thrombopoietin substitute
EP1950300A3 (de) 1998-11-18 2011-03-23 Genentech, Inc. Antikörpervarianten mit höherer Bindungsaffinität im Vergleich zu verwandten Antikörpern
AUPP785098A0 (en) 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
EP2075335A3 (de) 1998-12-22 2009-09-30 Genentech, Inc. Verfahren und Zusammensetzungen zur Hemmung des neoplastischen Zellenwachstums
AU778759B2 (en) 1998-12-23 2004-12-16 Genentech Inc. IL-1 related polypeptides
WO2000044390A1 (en) * 1999-02-01 2000-08-03 John Lezdey Treatment of bladder and gastrointestinal mastocytosis
IL145775A0 (en) 1999-04-12 2002-07-25 Agensys Inc 13 transmembrane protein expressed in prostate cancer
EP1792989A1 (de) 1999-04-12 2007-06-06 Agensys, Inc. 13-Transmembrane Protein welches in Prostatakrebs exprimiert wird
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
DE60043322D1 (de) 1999-06-15 2009-12-24 Genentech Inc Sekretierte und Transmembran-Polypeptide sowie Nukleinsäuren zu deren Kodierung
ATE420175T1 (de) 1999-08-12 2009-01-15 Agensys Inc C-typ lektin transmembranantigen, das in menschlichen prostatkrebs exprimiert wird, und deren verwendungen
US7459540B1 (en) * 1999-09-07 2008-12-02 Amgen Inc. Fibroblast growth factor-like polypeptides
DE60024101T2 (de) 1999-09-10 2006-07-27 The Procter & Gamble Company, Cincinnati Enzyminhibitoren
US6723788B1 (en) 1999-09-10 2004-04-20 The Procter & Gamble Company Enzyme inhibitors
IL147952A0 (en) 1999-10-05 2002-08-14 Agensys Inc G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US20030190644A1 (en) 1999-10-13 2003-10-09 Andreas Braun Methods for generating databases and databases for identifying polymorphic genetic markers
US6893818B1 (en) * 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
ATE364689T1 (de) 1999-11-18 2007-07-15 Dendreon Corp Nukleinsäuren, welche für endotheliasen kodieren, endotheliasen, sowie deren verwendung
US6703480B1 (en) * 1999-11-24 2004-03-09 Palani Balu Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US6462180B1 (en) 1999-11-24 2002-10-08 Bayer Corporation Method of preparing α-1 proteinase inhibitor
CA2491610A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
DK1897944T3 (da) 1999-12-23 2011-10-24 Genentech Inc IL-17 homologe polypeptider og terapeutisk anvendelse deraf
DE60137829D1 (de) 2000-01-13 2009-04-16 Genentech Inc Menschliche stra6 polypeptide
US7700341B2 (en) * 2000-02-03 2010-04-20 Dendreon Corporation Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon
ES2267593T3 (es) 2000-02-16 2007-03-16 Genentech, Inc. Anticuerpos anti-april y celulas hibridomas.
US7101974B2 (en) 2000-03-02 2006-09-05 Xencor TNF-αvariants
US6740520B2 (en) * 2000-03-21 2004-05-25 Genentech, Inc. Cytokine receptor and nucleic acids encoding the same
US20040086970A1 (en) * 2000-03-22 2004-05-06 Genentech, Inc. Novel cytokine receptors and nucleic acids encoding the same
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
WO2001093846A2 (en) * 2000-05-23 2001-12-13 The Trustees Of Columbia University In The City Of New York Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of clycosaminoglycans
CA2648046A1 (en) 2000-06-23 2002-01-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2275549A1 (de) 2000-06-23 2011-01-19 Genentech, Inc. Zusammensetzungen und Verfahren zur Diagnose und Behandlung von Erkrankungen in Verbindung mit Angiogenese
FR2811323B1 (fr) * 2000-07-07 2006-10-06 Fuma Tech Gmbh Materiau hybride, utilisation dudit materiau hybride et procede de sa fabrication
ATE412009T1 (de) 2000-08-24 2008-11-15 Genentech Inc Methode zur inhibierung von il-22 induziertem pap1
CA2420990C (en) 2000-08-28 2010-08-17 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
EP1944317A3 (de) 2000-09-01 2008-09-17 Genentech, Inc. Sekretierte und Transmembran-Polypeptide sowie Nukleinsäure zu deren Kodierung
US20020164576A1 (en) * 2000-09-22 2002-11-07 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
US20020115058A1 (en) * 2000-09-22 2002-08-22 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1
US6576452B1 (en) * 2000-10-04 2003-06-10 Genencor International, Inc. 2,5-diketo-L-gluconic acid reductases and methods of use
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US7700274B2 (en) * 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US20030232334A1 (en) * 2000-12-22 2003-12-18 Morris David W. Novel compositions and methods for cancer
US7820447B2 (en) 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US20030165878A1 (en) * 2000-12-22 2003-09-04 Morris David W. Novel compositions and methods in cancer associated with altered expression of MCM3AP
US20030087252A1 (en) * 2000-12-22 2003-05-08 Morris David W. Novel compositions and methods in cancer associated with altered expression of PRDM11
US7892730B2 (en) * 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US7645441B2 (en) * 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US20030099963A1 (en) * 2000-12-22 2003-05-29 Morris David W. Novel compositions and methods in cancer associated with altered expression of TBX21
US7829084B2 (en) * 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
CA2438656A1 (en) * 2001-02-14 2002-08-22 The Trustees Of Columbia University In The City Of New York Method for the prevention of tissue elastic fiber injury
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
AU2002305052A1 (en) 2001-03-13 2002-09-24 Corvas International, Inc. Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
JP2004535166A (ja) 2001-03-22 2004-11-25 デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー セリンプロテアーゼｃｖｓｐ１４をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
EP1379637A4 (de) 2001-03-27 2005-04-06 Dendreon Corp Transmembran-serinprotease 9 codierende nukleinsäuremoleküle, die codierten polypeptide sowie darauf beruhende verfahren
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
EE05294B1 (et) * 2001-05-11 2010-04-15 Amgen Inc. TALL-1-ga seostuv ainekompositsioon
JP2005506832A (ja) 2001-05-14 2005-03-10 デンドレオン・サンディエゴ・リミテッド・ライアビリティ・カンパニー トランスメンブランセリンプロテアーゼ１０をコードする核酸分子、コードされるポリペプチドおよびそれに基づく方法
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
KR100788092B1 (ko) 2001-06-20 2007-12-21 제넨테크, 인크. 종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
MXPA04001050A (es) * 2001-08-03 2004-07-08 Genentech Inc Polipeptidos tacis y br3 y usos de los mismos.
CN101884784B (zh) 2001-08-29 2014-03-12 杰南技术公司 具有促细胞分裂活性的Bv8的核酸和多肽
US20040235068A1 (en) * 2001-09-05 2004-11-25 Levinson Arthur D. Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
ES2537074T3 (es) 2001-09-06 2015-06-02 Agensys, Inc. Ácido nucleico y proteína correspondiente denominados STEAP-1 útiles en el tratamiento y la detección de cáncer
DE60238143D1 (de) 2001-09-18 2010-12-09 Genentech Inc Zusammensetzungen und verfahren für die diagnose von tumoren
US20070098728A1 (en) * 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
US7399613B2 (en) * 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7297511B2 (en) * 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US7265084B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7439043B2 (en) * 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7795210B2 (en) * 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7226903B2 (en) * 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7265085B2 (en) * 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
EP2298354B1 (de) 2001-10-10 2014-03-19 ratiopharm GmbH Neumodulierung und Glykokonjugation von Interferon-beta
US8008252B2 (en) * 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
CN101724075B (zh) 2001-10-10 2014-04-30 诺和诺德公司 肽的重构和糖缀合
US7157277B2 (en) * 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7173003B2 (en) * 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7125843B2 (en) * 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20030134794A1 (en) * 2001-11-20 2003-07-17 Madison Edwin L. Nucleic acid molecules encoding serine protease 17, the encoded polypeptides and methods based thereon
US7473680B2 (en) * 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
US20040180344A1 (en) * 2003-03-14 2004-09-16 Morris David W. Novel therapeutic targets in cancer
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
WO2003050276A1 (en) * 2001-12-05 2003-06-19 Dow Global Technologies Inc. Method for immobilizing a biologic in a polyurethane-hydrogel composition, a composition prepared from the method, and biomedical applications
MXPA04006554A (es) 2002-01-02 2005-03-31 Genentech Inc Composiciones y metodos para diagnostico y tratamiento de tumor.
WO2003072714A2 (en) 2002-02-21 2003-09-04 Wyeth Follistatin domain containing proteins
JP2005535290A (ja) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
SI1485477T1 (sl) 2002-02-25 2009-10-31 Genentech Inc Novi citokinski receptor GLM-R tipa 1
US20100311954A1 (en) * 2002-03-01 2010-12-09 Xencor, Inc. Optimized Proteins that Target Ep-CAM
DE10209821A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung von Proteinen an ein modifiziertes Polysaccharid
DE10209822A1 (de) * 2002-03-06 2003-09-25 Biotechnologie Ges Mittelhesse Kopplung niedermolekularer Substanzen an ein modifiziertes Polysaccharid
CA2479730A1 (en) * 2002-03-21 2003-10-02 Sagres Discovery, Inc. Novel compositions and methods in cancer
EP2011886A3 (de) 2002-04-16 2009-02-11 Genentech, Inc. Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
AU2003228809A1 (en) * 2002-05-03 2003-11-17 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
WO2003103725A1 (en) * 2002-06-07 2003-12-18 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
MXPA04012496A (es) * 2002-06-21 2005-09-12 Novo Nordisk Healthcare Ag Glicoformos del factor vii pegilados.
WO2004004649A2 (en) 2002-07-08 2004-01-15 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
CA2492447A1 (en) * 2002-07-25 2004-02-05 Genentech, Inc. Taci antibodies and uses thereof
CN100594239C (zh) * 2002-08-12 2010-03-17 金克克国际有限公司 大肠杆菌appa肌醇六磷酸酶突变体
WO2004016733A2 (en) 2002-08-16 2004-02-26 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
US20040091490A1 (en) * 2002-08-28 2004-05-13 Robert Johnson Stable pH optimized formulation of a modified antibody
WO2004019860A2 (en) * 2002-08-28 2004-03-11 Pharmacia Corporation Formulations of modified antibodies and methods of making the same
WO2004024068A2 (en) 2002-09-11 2004-03-25 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
WO2004024072A2 (en) 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
CN100348618C (zh) * 2002-09-11 2007-11-14 弗雷泽纽斯卡比德国有限公司 生产羟烷基淀粉衍生物的方法
JP2006515165A (ja) 2002-09-16 2006-05-25 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
AU2003275077B2 (en) 2002-09-18 2010-02-04 Ortho-Mcneil Pharmaceutical, Inc. Methods of increasing platelet and hematopoietic stem cell production
WO2004028479A2 (en) 2002-09-25 2004-04-08 Genentech, Inc. Nouvelles compositions et methodes de traitement du psoriasis
US20040149235A1 (en) * 2002-10-04 2004-08-05 Pogue Albert S. Apparatus and method for removal of waste from animal production facilities
JP2006517785A (ja) 2002-10-29 2006-08-03 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための新規組成物と方法
EP1560597A4 (de) * 2002-10-29 2007-06-27 Pharmacia Corp Differentiell ausgedrückte krebsgene, dabei kodierte polypeptide und verfahren zu ihrer verwendung
AU2003295401B2 (en) 2002-11-08 2010-04-29 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004050828A2 (en) 2002-11-27 2004-06-17 Agensys, Inc. Nucleic acid corresponding protein entitled 24p4c12 useful in treatment and detection of cancer
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
AU2003303513A1 (en) * 2002-12-30 2004-07-29 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
US20050221443A1 (en) * 2003-01-06 2005-10-06 Xencor, Inc. Tumor necrosis factor super family agonists
US20050130892A1 (en) * 2003-03-07 2005-06-16 Xencor, Inc. BAFF variants and methods thereof
US7553930B2 (en) * 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
US20060014248A1 (en) * 2003-01-06 2006-01-19 Xencor, Inc. TNF super family members with altered immunogenicity
WO2004063963A2 (en) * 2003-01-08 2004-07-29 Xencor, Inc. Novel proteins with altered immunogenicity
WO2004072263A2 (en) 2003-02-10 2004-08-26 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US7767387B2 (en) * 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
US20070218071A1 (en) * 2003-09-15 2007-09-20 Morris David W Novel therapeutic targets in cancer
JP2007524362A (ja) 2003-02-14 2007-08-30 サイグレス ディスカバリー， インコーポレイテッド 癌における治療ｇｐｃｒ標的
MXPA05009743A (es) 2003-03-12 2006-03-09 Genentech Inc Composiciones con actividad hematopoyetica e inmune.
CA2519092C (en) * 2003-03-14 2014-08-05 Neose Technologies, Inc. Branched water-soluble polymers and their conjugates
ES2340280T3 (es) * 2003-03-14 2010-06-01 Wyeth Llc Anticuerpos dirigidos contra el receptor de il-21 humano y uso de los mismos.
US7691603B2 (en) * 2003-04-09 2010-04-06 Novo Nordisk A/S Intracellular formation of peptide conjugates
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US20070026485A1 (en) * 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
BRPI0410164A (pt) 2003-05-09 2006-05-16 Neose Technologies Inc composições e métodos para preparação de mutantes de glicosilação de hormÈnio do crescimento humano
RS20181002A1 (sr) 2003-05-30 2018-12-31 Genentech Inc Tretman sa anti-vegf antitelima
NZ578591A (en) 2003-05-30 2011-01-28 Agensys Inc Prostate stem cell antigen (PSCA) variants and subsequences thereof, namely SEQ ID NO: 6554
BRPI0411276A (pt) * 2003-06-05 2006-08-01 Genentech Inc métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
US7939058B2 (en) * 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
KR100945327B1 (ko) 2003-07-08 2010-03-08 제넨테크, 인크. Ｉｌ-１７ａ／ｆ 이종 폴리펩티드 및 그의 치료 용도
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
TW201319088A (zh) 2003-07-18 2013-05-16 Amgen Inc 對肝細胞生長因子具專一性之結合劑
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
WO2005014655A2 (en) 2003-08-08 2005-02-17 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
SG145746A1 (en) * 2003-08-08 2008-09-29 Fresenius Kabi De Gmbh Conjugates of hydroxyalkyl starch and g-csf
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050054614A1 (en) * 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
WO2005016348A1 (en) * 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
AR045614A1 (es) * 2003-09-10 2005-11-02 Hoffmann La Roche Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US20060134105A1 (en) * 2004-10-21 2006-06-22 Xencor, Inc. IgG immunoglobulin variants with optimized effector function
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US20070281896A1 (en) * 2003-09-30 2007-12-06 Morris David W Novel compositions and methods in cancer
US20070274988A1 (en) * 2003-10-10 2007-11-29 Five Prime Therapeautics, Inc. Kiaa0779, Splice Variants Thereof, and Methods of Their Use
CA2542353A1 (en) 2003-10-10 2005-04-21 Xencor, Inc. Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
EP2412725A3 (de) 2003-11-17 2012-04-25 Genentech, Inc. Antikörper gegen CD79b zur Behandlung von Tumoren hämatopoetischen Ursprungs
US8633157B2 (en) * 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) * 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7842661B2 (en) * 2003-11-24 2010-11-30 Novo Nordisk A/S Glycopegylated erythropoietin formulations
US20070254834A1 (en) * 2003-11-24 2007-11-01 Defrees Shawn Glycopegylated Erythropoietin
NZ547554A (en) * 2003-12-03 2009-09-25 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
US20080318850A1 (en) * 2003-12-03 2008-12-25 Neose Technologies, Inc. Glycopegylated Factor Ix
US7956032B2 (en) * 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
EP3476861A1 (de) 2004-01-07 2019-05-01 Novartis Vaccines and Diagnostics, Inc. M-csf-spezifischer monoklonaler antikörper und verwendungen davon
CA2552892C (en) * 2004-01-08 2014-08-05 Neose Technologies, Inc. O-linked glycosylation of peptides
US20050169970A1 (en) * 2004-02-02 2005-08-04 Unilever Bestfoods, North America Food composition with fibers
WO2005092928A1 (en) * 2004-03-11 2005-10-06 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
ES2390885T3 (es) * 2004-03-11 2012-11-19 Fresenius Kabi Deutschland Gmbh Conjugados de hidroxialquilalmidón y una proteína
RU2386638C2 (ru) * 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7794713B2 (en) * 2004-04-07 2010-09-14 Lpath, Inc. Compositions and methods for the treatment and prevention of hyperproliferative diseases
DK1737891T3 (da) 2004-04-13 2013-03-25 Hoffmann La Roche Anti-p-selectin-antistoffer
WO2006083260A2 (en) 2004-04-28 2006-08-10 Angiotech Biomaterials Corporation Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
RU2006138181A (ru) 2004-05-04 2008-06-10 Ново Нордиск Хелс Кеа Аг (Ch) О-связанные гликоформы полипептидов и способ их изготовления
ES2605792T3 (es) 2004-05-13 2017-03-16 Icos Corporation Quinazolinona usada como inhibidor de la fosfatidilinositol 3-quinasa delta humana
JP2008500338A (ja) * 2004-05-25 2008-01-10 イコス・コーポレイション 造血細胞の異常増殖を治療及び／又は予防する方法
NZ551627A (en) 2004-05-28 2010-02-26 Agensys Inc Antibodies and related molecules that bind to PSCA proteins
US20060014680A1 (en) * 2004-07-13 2006-01-19 Caiding Xu Peptides and compounds that bind to the IL-5 receptor
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
AU2005269716B2 (en) 2004-07-20 2011-01-27 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
EP1799249A2 (de) * 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegyliertes interferon alpha
TWI309240B (en) * 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
CA2581093C (en) 2004-09-17 2014-11-18 Angiotech Biomaterials Corporation Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
US20060204512A1 (en) 2004-09-23 2006-09-14 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
DK1797127T3 (en) * 2004-09-24 2017-10-02 Amgen Inc Modified Fc molecules
JP2008514215A (ja) * 2004-09-29 2008-05-08 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 改変タンパク質
EP1812474B1 (de) 2004-10-15 2010-05-26 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
US20080176790A1 (en) 2004-10-29 2008-07-24 Defrees Shawn Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
EP2325207B1 (de) 2004-11-12 2017-03-15 Xencor, Inc. Fc-varianten mit modifizierter bindung an fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
DE602005022928D1 (de) 2004-11-30 2010-09-23 Abgenix Inc Antikörper gegen gpnmb und ihre verwendungen
US20060134698A1 (en) * 2004-12-20 2006-06-22 Evanston Northwestern Healthcare Research Institute Methods for treating cardiac disease by modifying an N-terminal domain of troponin I
US20100009902A1 (en) * 2005-01-06 2010-01-14 Neose Technologies, Inc. Glycoconjugation Using Saccharyl Fragments
EP1858543B1 (de) 2005-01-10 2013-11-27 BioGeneriX AG Glycopegylierten Granulocyten-Kolonie-stimulierender Faktor
AU2006208226A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
EP1885356A2 (de) * 2005-02-17 2008-02-13 Icos Corporation Phophoinositid-3-kinaseinhibitoren zur hemmung der leukozytenakkumulation
CA2598528A1 (en) * 2005-03-11 2006-09-14 Fresenius Kabi Deutschland Gmbh Production of bioactive glycoproteins from inactive starting material
EP1866427A4 (de) * 2005-03-30 2010-09-01 Novo Nordisk As Herstellungsverfahren zur produktion von in insektenzelllinien entstandenen peptiden
EP2444099A1 (de) 2005-03-31 2012-04-25 Agensys, Inc. An 161P2F10B-Proteine bindende Antikörper und zugehörige Moleküle
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof
US20090214536A1 (en) 2005-04-07 2009-08-27 Guoying Yu CACNA1E in Cancer Diagnosis, Detection and Treatment
EP1871911A2 (de) 2005-04-07 2008-01-02 Chiron Corporation Gene in verbindung mit krebs (prlr)
US9187546B2 (en) * 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US20060271262A1 (en) * 2005-05-24 2006-11-30 Mclain Harry P Iii Wireless agricultural network
US20080255026A1 (en) 2005-05-25 2008-10-16 Glycopegylated Factor 1X Glycopegylated Factor Ix
WO2008018854A2 (en) * 2005-06-06 2008-02-14 The Rockefeller University Bactiophage lysins for bacillus anthracis
JP2008541781A (ja) 2005-06-06 2008-11-27 ジェネンテック・インコーポレーテッド 異なる遺伝子に対するトランスジェニック動物、および遺伝子の特徴づけのためのその使用
WO2006138145A1 (en) 2005-06-14 2006-12-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
US7582291B2 (en) * 2005-06-30 2009-09-01 The Rockefeller University Bacteriophage lysins for Enterococcus faecalis, Enterococcus faecium and other bacteria
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
SI2298815T1 (sl) * 2005-07-25 2015-08-31 Emergent Product Development Seattle, Llc Zmanjšanje števila celic b z uporabo molekul, ki se specifično vežejo na cd37 in cd20
WO2007016285A2 (en) * 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
EP2277916A3 (de) * 2005-07-28 2011-04-27 Novartis AG Verwendung von Antikörper zu M-CSF
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
JP2009504183A (ja) 2005-08-15 2009-02-05 ジェネンテック・インコーポレーテッド 遺伝子破壊、それに関連する組成物および方法
CN102719508A (zh) * 2005-08-19 2012-10-10 诺和诺德公司 糖基聚乙二醇化的因子vii和因子viia
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US8105585B2 (en) * 2005-08-24 2012-01-31 The Rockefeller Universtiy Ply-GBS mutant lysins
EP1762250A1 (de) * 2005-09-12 2007-03-14 Fresenius Kabi Deutschland GmbH Konjugate welche durch chemische Ligation zwischen Hydroxyalkylstärken und aktiven Substanzen mit Bildung eines Thiazolidin-Ringes entstehen
CA2624900A1 (en) * 2005-10-04 2007-04-19 The Research Foundation Of State University Of New York Fibronectin polypeptides and methods of use
US20090074720A1 (en) * 2005-10-28 2009-03-19 Sabbadini Roger A Methods for decreasing immune response and treating immune conditions
US20080213274A1 (en) * 2005-10-28 2008-09-04 Sabbadini Roger A Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
US20090048440A1 (en) * 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CN101360826B (zh) 2005-11-18 2014-04-30 格兰马克药品股份有限公司 抗α2整联蛋白抗体及它们的用途
CA2630432A1 (en) 2005-11-21 2007-07-19 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
JP6088723B2 (ja) * 2005-11-23 2017-03-01 ジェネンテック， インコーポレイテッド Ｂ細胞アッセイに関する組成物及び方法。
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
CA2841386A1 (en) 2005-12-30 2007-07-12 Zensun (Shanghai) Science & Technology Limited Extended release of neuregulin for improved cardiac function
US9012605B2 (en) 2006-01-23 2015-04-21 Amgen Inc. Crystalline polypeptides
TW200745163A (en) 2006-02-17 2007-12-16 Syntonix Pharmaceuticals Inc Peptides that block the binding of IgG to FcRn
WO2007114979A2 (en) 2006-02-17 2007-10-11 Genentech, Inc. Gene disruptons, compositions and methods relating thereto
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
WO2007111661A2 (en) 2006-03-20 2007-10-04 Xoma Technology Ltd. Human antibodies specific for gastrin materials and methods
PL1989231T3 (pl) 2006-03-21 2015-10-30 Genentech Inc Terapia kombinatoryczna z udziałem antagonistów alfa5beta1
EP2004697A2 (de) 2006-04-07 2008-12-24 The Procter & Gamble Company An die humane proteintyrosinphosphatase-beta (hptp-beta) bindende antikörper und anwendungen davon
US20090288176A1 (en) 2006-04-19 2009-11-19 Genentech, Inc. Novel Gene Disruptions, Compositions and Methods Relating Thereto
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
US7862812B2 (en) * 2006-05-31 2011-01-04 Lpath, Inc. Methods for decreasing immune response and treating immune conditions
NZ573646A (en) * 2006-06-12 2012-04-27 Wyeth Llc Single-chain multivalent binding proteins with effector function
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
EP2041174A2 (de) * 2006-06-16 2009-04-01 Lipid Sciences, Inc. Neue, den lipidausstrom fördernde peptide
US7981425B2 (en) * 2006-06-19 2011-07-19 Amgen Inc. Thrombopoietic compounds
EP2452683A3 (de) 2006-06-26 2012-08-22 Amgen Inc. Verfahren zur Behandlung von Atherosklerose
CN101516388B (zh) * 2006-07-21 2012-10-31 诺和诺德公司 通过o-联糖基化序列的肽的糖基化
JP5406027B2 (ja) 2006-08-04 2014-02-05 ノバルティス アーゲー ＥｐｈＢ３特異的抗体およびその使用
AR062435A1 (es) 2006-08-18 2008-11-05 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
WO2008039843A2 (en) * 2006-09-26 2008-04-03 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
JP4960459B2 (ja) 2006-09-29 2012-06-27 エフ．ホフマン−ラ ロシュ アーゲー Ｃｃｒ５に対する抗体およびその使用
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
US8969532B2 (en) * 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
CA2665480C (en) * 2006-10-04 2019-11-12 Shawn Defrees Glycerol linked pegylated sugars and glycopeptides
EP1914303A1 (de) * 2006-10-09 2008-04-23 Qiagen GmbH Thermus eggertssonii DNA Polymerasen
CN101687031B (zh) 2006-10-27 2014-05-14 勒帕斯公司 用于治疗眼疾和眼病的组合物及方法
JP5795833B2 (ja) * 2006-10-27 2015-10-14 エルパス・インコーポレイテッドＬｐａｔｈ， Ｉｎｃ． スフィンゴシン−１−リン酸と結合させるための組成物および方法
MX2009004664A (es) 2006-11-02 2009-10-12 Daniel J Capon Inmunoglobulinas hibridas con partes moviles.
WO2008073620A2 (en) * 2006-11-02 2008-06-19 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
WO2008061013A2 (en) 2006-11-10 2008-05-22 Amgen Inc. Antibody-based diagnostics and therapeutics
EP2097422A4 (de) * 2006-11-13 2010-04-14 Lilly Co Eli Thienopyrimidinone zur behandlung von entzündungserkrankungen und karzinomen
NZ576272A (en) 2006-11-14 2012-01-12 Genentech Inc Modulators of neuronal regeneration
EP3156415A1 (de) 2006-11-22 2017-04-19 Bristol-Myers Squibb Company Gezielte therapeutik auf grundlage manipulierter proteine für tyrosinkinaserezeptoren, einschliesslich igf-ir
MX2009006034A (es) 2006-12-07 2009-10-12 Novartis Ag Anticuerpos antagonistas contra ephb3.
US7943728B2 (en) 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
US8183201B2 (en) * 2006-12-26 2012-05-22 National Cheng Kung University Methods of treating αvβ3 integrin-associated diseases by administering polypeptides selective for αvβ3 integrin
WO2008091222A1 (en) * 2007-01-26 2008-07-31 Bioinvent International Ab Dll4 signaling inhibitors and uses thereof
MX2009008104A (es) * 2007-02-02 2009-08-07 Amgen Inc Hepcidina, antagonistas de hepcidina y metodos de uso.
ATE516814T1 (de) 2007-02-02 2011-08-15 Bristol Myers Squibb Co 10fn3 domain zur behandlung von krankheiten begleitet von unerwünschter angiogenese
US8507200B2 (en) * 2007-02-09 2013-08-13 Northwestern University Particles for detecting intracellular targets
US8088887B2 (en) * 2007-02-13 2012-01-03 Academia Sinica Peptide-conjugates that bind to VEGF-stimulated or tumor vasculature and methods of treatment
US8415453B2 (en) * 2007-02-13 2013-04-09 Academia Sinica Lung cancer-targeted peptides and applications thereof
CA2676790A1 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
DK2144923T3 (da) * 2007-04-03 2013-05-13 Biogenerix Ag Behandlingsfremgangsmåder under anvendelse af glycopegyleret g-csf
US20090053167A1 (en) * 2007-05-14 2009-02-26 Neose Technologies, Inc. C-, S- and N-glycosylation of peptides
US9163091B2 (en) * 2007-05-30 2015-10-20 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
WO2008151049A2 (en) 2007-05-30 2008-12-11 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
WO2008150841A1 (en) 2007-05-30 2008-12-11 Lpath, Inc. Compositions and methods for binding lysophosphatidic acid
JP2010531135A (ja) * 2007-06-04 2010-09-24 ノボ ノルディスク アクティーゼルスカブ Ｎ−アセチルグルコサミニルトランスフェラーゼを使用したｏ結合型グリコシル化
ES2551123T3 (es) * 2007-06-12 2015-11-16 Ratiopharm Gmbh Proceso mejorado para la producción de azúcares de nucleótido
CA2690734A1 (en) * 2007-06-14 2008-12-24 Richard A. Clark Polypeptides and methods of use
US7625555B2 (en) 2007-06-18 2009-12-01 Novagen Holding Corporation Recombinant human interferon-like proteins
AU2008287195A1 (en) * 2007-07-06 2009-02-19 Emergent Product Development Seattle, Llc Binding peptides having a C-terminally disposed specific binding domain
SG183023A1 (en) 2007-07-16 2012-08-30 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
EP2641618A3 (de) 2007-07-16 2013-10-23 Genentech, Inc. Humanisierte Anti-CD79b Antikörper und Immunkonjugate sowie Verwendungsverfahren
SI2489731T1 (sl) 2007-07-26 2014-12-31 Amgen Inc. Patent Operations, M/S 28-2-C Modificirani encimi lecitin-holesterol aciltransferaze
CN101361968B (zh) 2007-08-06 2011-08-03 健能隆医药技术（上海）有限公司 白介素-22在治疗脂肪肝中的应用
EA201070231A1 (ru) * 2007-08-09 2010-10-29 Синтоникс Фармасьютикалз, Инк. Иммуномодулирующие пептиды
EP2615114B1 (de) 2007-08-23 2022-04-06 Amgen Inc. Antigenbindende Proteine an Proprotein-Konvertase-Subtilisin/Kexin vom Typ 9 (PCSK9)
JOP20080381B1 (ar) 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
SI2197919T1 (sl) 2007-08-27 2014-09-30 Ratiopharm Gmbh Tekoäśa formulacija g-csf konjugata
CN111909273B (zh) 2007-08-29 2024-03-26 塞诺菲-安万特股份有限公司 人源化的抗-cxcr5抗体、其衍生物及它们的应用
US8207112B2 (en) * 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
US20090156488A1 (en) 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
EP2050764A1 (de) 2007-10-15 2009-04-22 sanofi-aventis Neues polyvalentes bispezifisches Antikörperformat und Verwendung
US8361465B2 (en) * 2007-10-26 2013-01-29 Lpath, Inc. Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
KR101383476B1 (ko) 2007-11-01 2014-04-11 아스테라스 세이야쿠 가부시키가이샤 면역억제 폴리펩티드 및 핵산
US8541543B2 (en) * 2007-11-20 2013-09-24 Academia Sinica Peptides specific for hepatocellular carcinoma cells and applications thereof
EP2231181B1 (de) 2007-12-17 2016-02-17 Marfl AB Neuer impfstoff zur behandlung von erkrankungen durch myobacterium
US8414893B2 (en) 2007-12-21 2013-04-09 Amgen Inc. Anti-amyloid antibodies and uses thereof
HUE024903T2 (en) 2007-12-26 2016-02-29 Xencor Inc FC variants with modified binding to FCRN
JP5647899B2 (ja) * 2008-01-08 2015-01-07 ラツィオファルム ゲーエムベーハーｒａｔｉｏｐｈａｒｍ ＧｍｂＨ オリゴサッカリルトランスフェラーゼを使用するポリペプチドの複合糖質化
KR20180041269A (ko) 2008-01-22 2018-04-23 아라임 파마슈티칼즈, 인크. 조직 손상 관련 질환 및 장애를 예방 및 치료하기 위한 조직 보호 펩티드 및 펩티드 유사체
JP5701064B2 (ja) 2008-01-25 2015-04-15 アムジエン・インコーポレーテツド フェロポーチン抗体およびその使用方法
IL295449A (en) 2008-01-31 2022-10-01 Genentech Inc and fusion antibody-drug-cd79b engineered antibodies cysteine-
ES2848323T3 (es) 2008-01-31 2021-08-06 Inst Nat Sante Rech Med Anticuerpos contra CD39 humano y uso de los mismos para inhibir la actividad de las células T reguladoras
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CN101965200B (zh) 2008-02-27 2013-06-19 诺沃-诺迪斯克有限公司 缀合的因子ⅷ分子
HUE036780T2 (hu) 2008-04-09 2018-07-30 Genentech Inc Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
US8697081B2 (en) * 2008-04-09 2014-04-15 The Regents Of The University Of Michigan Method of modulating neovascularization
WO2009126944A1 (en) * 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
US8921315B1 (en) 2008-04-24 2014-12-30 Neumedicines, Inc. Method of increasing survival of a human subject having exposure to an acute exposure to non-therapeutic whole body ionization by administering a therapeutically effective dose of IL-12
ES2487846T3 (es) 2008-05-01 2014-08-25 Amgen, Inc. Anticuerpos anti-hepcindina y métodos de uso
EP2279405B1 (de) 2008-05-13 2013-09-18 Advanced Liquid Logic, Inc. Tropfenaktuatorvorrichtungen, systeme und verfahren
CA2724415C (en) 2008-05-15 2016-09-13 Selexys Pharmaceuticals Corporation Anti-psgl-1 antibodies and methods of identification and use
US8093018B2 (en) 2008-05-20 2012-01-10 Otsuka Pharmaceutical Co., Ltd. Antibody identifying an antigen-bound antibody and an antigen-unbound antibody, and method for preparing the same
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
JOP20190083A1 (ar) 2008-06-04 2017-06-16 Amgen Inc بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها
WO2010002895A2 (en) * 2008-06-30 2010-01-07 The Regents Of The University Of Michigan Lysosomal phospholipase a2 (lpla2) activity as a diagnostic and therapeutic target for identifying and treating systemic lupus erythematosis
US20100048488A1 (en) * 2008-08-01 2010-02-25 Syntonix Pharmaceuticals, Inc. Immunomodulatory peptides
BRPI0823049A2 (pt) 2008-09-07 2015-06-16 Glyconex Inc Anticorpos para glicoesfingolipídeos tipo 1 anti-estendidos, derivados dos mesmos e uso.
WO2010040105A2 (en) 2008-10-02 2010-04-08 Trubion Pharmaceuticals, Inc. Cd86 antagonist multi-target binding proteins
EP2355847A1 (de) 2008-10-07 2011-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Neutralisierende antikörper und fragmente davon gegen thrombozytenfaktor-4-variante 1 (pf4v1)
MX341149B (es) 2008-10-10 2016-08-09 Amgen Inc Mutantes fgf21 y uso de los mismos.
EP2340040B1 (de) 2008-10-22 2019-01-16 F.Hoffmann-La Roche Ag Modulierung von axonen-degeneration
US8871202B2 (en) 2008-10-24 2014-10-28 Lpath, Inc. Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
AU2009312532B2 (en) * 2008-11-06 2013-05-16 Ichnos Sciences SA Treatment with anti-alpha2 integrin antibodies
NZ592880A (en) 2008-11-13 2013-06-28 Gilead Calistoga Llc Combinations of purine derivatives and proteasome inhibitors such as bortezomib for the treatment of hematological malignancy
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
MX2011005429A (es) * 2008-11-24 2011-06-21 Univ Northwestern Composiciones de nanoparticulas de arn polivalentes.
BRPI0922344A2 (pt) 2008-12-19 2017-10-24 3B Pharmaceuticals Gmbh inibidores de tfpi e métodos de uso
US20100233270A1 (en) * 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US20100184844A1 (en) * 2009-01-08 2010-07-22 Northwestern University Inhibition of Bacterial Protein Production by Polyvalent Oligonucleotide Modified Nanoparticle Conjugates
US20100294952A1 (en) * 2009-01-15 2010-11-25 Northwestern University Controlled agent release and sequestration
EP3002296B1 (de) 2009-03-17 2020-04-29 Université d'Aix-Marseille Btla-antikörper und ihre verwendung
CA3018235C (en) 2009-03-20 2021-01-12 Amgen Inc. Carrier immunoglobulins and uses thereof
CA2756347A1 (en) 2009-03-24 2010-09-30 Gilead Calistoga Llc Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
SG10201609416XA (en) 2009-03-25 2016-12-29 Genentech Inc NOVEL ANTI-α5ß1 ANTIBODIES AND USES THEREOF
KR101766927B1 (ko) 2009-04-01 2017-08-09 제넨테크, 인크. 인슐린 저항성 장애의 치료
PE20120878A1 (es) 2009-04-01 2012-08-06 Genentech Inc ANTICUERPOS ANTI-FcRH5 E INMUNOCONJUGADOS
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
US8067201B2 (en) * 2009-04-17 2011-11-29 Bristol-Myers Squibb Company Methods for protein refolding
WO2010123931A1 (en) * 2009-04-20 2010-10-28 Calistoga Pharmaceuticals Inc. Methods of treatment for solid tumors
EP2248903A1 (de) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Verfahren und Reagenzien zum effizienten und gezielten Gentransfer in Monozyten und Makrophagen
AU2010246038A1 (en) 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
SI3248610T1 (sl) 2009-05-05 2024-03-29 Amgen Inc., Mutanti fgf21 in njihove uporabe
TW201102086A (en) 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
BRPI1011236A2 (pt) 2009-06-15 2019-07-09 4S3 Bioscience Inc métodos e composições para tratamento de miopatia miotubular usando polipeptídeos quiméricos compreendendo polipeptídeos miotubularesih 1 (mtm1)
WO2010148142A1 (en) 2009-06-17 2010-12-23 Amgen Inc. Chimeric fgf19 polypeptides and uses thereof
CN102470156A (zh) * 2009-07-20 2012-05-23 成功大学 选择性作用于αvβ3整合素并缀合人血清白蛋白(HSA)变体的多肽及其药学用途
JP2013500257A (ja) 2009-07-21 2013-01-07 ギリアード カリストガ エルエルシー Ｐｉ３ｋインヒビターでの肝障害の処置
US20110027275A1 (en) 2009-07-31 2011-02-03 Napoleone Ferrara Inhibition of tumor metastasis
JP5885664B2 (ja) 2009-09-25 2016-03-15 ゾーマ テクノロジー リミテッド スクリーニング法
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
AU2010308030B2 (en) 2009-10-12 2014-05-29 Pfizer Inc. Cancer treatment
TW201117824A (en) 2009-10-12 2011-06-01 Amgen Inc Use of IL-17 receptor a antigen binding proteins
MX368790B (es) * 2009-10-15 2019-10-16 Genentech Inc Factores de crecimiento de fibroblasto quimericos con especificidad de receptor alterada.
WO2011049625A1 (en) 2009-10-20 2011-04-28 Mansour Samadpour Method for aflatoxin screening of products
RU2539772C2 (ru) 2009-10-22 2015-01-27 Дженентек, Инк. Способы и композиции для модуляции гепсином стимулирующего макрофаги белка
EP3011970A3 (de) 2009-10-22 2016-06-08 F. Hoffmann-La Roche AG Modulation der axondegeneration
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
EP2494075B1 (de) 2009-10-30 2018-04-04 Northwestern University Templatgesteuerte nanokonjugate
LT2496567T (lt) 2009-11-05 2017-11-27 Rhizen Pharmaceuticals S.A. Nauji benzopirano kinazės moduliatoriai
TW201121570A (en) 2009-11-12 2011-07-01 Genentech Inc A method of promoting dendritic spine density
WO2011062997A2 (en) 2009-11-17 2011-05-26 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
AU2010321832B2 (en) 2009-11-20 2014-08-14 Amgen Inc. Anti-Orai1 antigen binding proteins and uses thereof
CN103755809B (zh) 2009-11-30 2016-06-01 霍夫曼-拉罗奇有限公司 治疗和诊断表达slc34a2(tat211=seqid2)的肿瘤的抗体
WO2011066511A1 (en) 2009-11-30 2011-06-03 The U.S.A., As Represented By The Secretary Department Of Health And Human Services Synthetic apoa-1 mimetic amphipathic peptides and methods of use thereof
AU2010326024A1 (en) * 2009-12-02 2012-07-05 Amgen Inc. Binding proteins that bind to human FGFR1c, human beta-Klotho and both human FGFR1c and human beta-Klotho
UA109888C2 (uk) * 2009-12-07 2015-10-26 ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ
EP2512600A2 (de) 2009-12-18 2012-10-24 Amgen Inc. Wise-bindemittel und epitope
RU2560583C2 (ru) 2009-12-22 2015-08-20 Рош Гликарт Аг Антитела к her3 и их применения
RU2012131251A (ru) 2009-12-23 2014-01-27 Нэйшнл Ченг Кунг Юниверсити Композиции и способы для лечения связанных с ангиогенезом заболеваний глаз
EP2516467A2 (de) 2009-12-23 2012-10-31 Emergent Product Development Seattle, LLC Zusammensetzungen mit tnf-alpha- und il-6-antagonisten und verwendungsverfahren dafür
EP2519544A1 (de) 2009-12-29 2012-11-07 Emergent Product Development Seattle, LLC Polypeptidheterodimere und ihre verwendung
US20110189178A1 (en) * 2010-02-04 2011-08-04 Xencor, Inc. Immunoprotection of Therapeutic Moieties Using Enhanced Fc Regions
WO2011097527A2 (en) 2010-02-04 2011-08-11 Xencor, Inc. Immunoprotection of therapeutic moieties using enhanced fc regions
CN104610454A (zh) 2010-02-16 2015-05-13 米迪缪尼有限公司 Hsa相关组合物及使用方法
AR080243A1 (es) 2010-02-23 2012-03-21 Genentech Inc Composiciones y metodos para el diagnostico y tratamiento de tumores
RU2545401C2 (ru) 2010-02-23 2015-03-27 Санофи Антитела к интегрину альфа-2 и их применения
US20110212088A1 (en) * 2010-02-26 2011-09-01 Sabbadini Roger A Anti-paf antibodies
CN102822198B (zh) 2010-03-12 2016-08-31 艾伯维生物医疗股份有限公司 Ctla4蛋白和其用途
JP5730983B2 (ja) 2010-03-19 2015-06-10 バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｉｎｃｏｒｐ０Ｒａｔｅｄ Ｔｆｐｉ阻害剤および使用方法
PT3178851T (pt) 2010-03-31 2020-07-17 Boehringer Ingelheim Int Anticorpos anti-cd40
EP2552443B1 (de) 2010-04-01 2021-07-14 Oncorena Ab Verbesserte behandlung von nierenzellenkarzinomen
WO2011130417A2 (en) 2010-04-15 2011-10-20 Amgen Inc. HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS
SG185027A1 (en) 2010-05-03 2012-11-29 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
CN103068824B (zh) 2010-05-17 2017-09-08 印蔻真治疗公司 作为蛋白激酶调节剂的新型3,5‑二取代‑3h‑咪唑并[4,5‑b]吡啶和3,5‑二取代‑3h‑[1,2,3]三唑并[4,5‑b]吡啶化合物
JP6267510B2 (ja) 2010-05-18 2018-01-24 ニューメディシンズ，インコーポレーテッド 造血を増強するためのｉｌ−１２製剤
CN103180339B (zh) 2010-05-26 2016-04-27 百时美施贵宝公司 具有改善的稳定性的基于纤连蛋白的支架蛋白质
EP2582387A2 (de) 2010-06-17 2013-04-24 The United States Of America As Represented By The Secretary, National Institutes Of Health Zusammensetzungen und verfahren zur behandlung von entzündungserkrankungen
AR082163A1 (es) 2010-07-15 2012-11-14 Hoffmann La Roche Anticuerpos especificamente ligantes del tslpr humano y metodos de utilizacion de los mismos
WO2012010696A1 (en) 2010-07-23 2012-01-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for cancer management targeting co-029
DK3029066T3 (da) 2010-07-29 2019-05-20 Xencor Inc Antistoffer med modificerede isoelektriske punkter
EP2603526A1 (de) 2010-08-13 2013-06-19 Medimmune Limited Monomere polypeptide mit abweichenden fc-regionen und verwendungsverfahren
KR101767860B1 (ko) 2010-08-20 2017-08-14 와이어쓰 엘엘씨 디자이너 골형성 단백질
US9688735B2 (en) 2010-08-20 2017-06-27 Wyeth Llc Designer osteogenic proteins
CN102380091A (zh) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 白介素-22在治疗病毒性肝炎中的应用
ES2535704T3 (es) 2010-09-14 2015-05-14 F. Hoffmann-La Roche Ag Polipéptido de fusión serpina-dedo
EA201370076A1 (ru) 2010-09-22 2013-08-30 Амген Инк. Иммуноглобулины-переносчики и их применение
EP2621954A1 (de) 2010-10-01 2013-08-07 Oxford Biotherapeutics Ltd. Anti-rori-antikörper
US9445990B2 (en) 2010-10-06 2016-09-20 Medtronic, Inc. TNF inhibitor formulation for use in implantable infusion devices
EP2633317A1 (de) 2010-10-25 2013-09-04 Genentech, Inc. Behandlung von magen-darm-entzündung und psoriasis a
EP3456740A1 (de) 2010-11-04 2019-03-20 Boehringer Ingelheim International GmbH Anti-il-23-antikörper
US9023791B2 (en) 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
WO2012080769A1 (en) 2010-12-15 2012-06-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-cd277 antibodies and uses thereof
PL2654781T3 (pl) 2010-12-21 2018-09-28 Novartis Ag Przeciwciała anty-p-selektynowe i sposoby ich zastosowania i identyfikacji
EP2654789B1 (de) 2010-12-22 2018-05-30 Orega Biotech Antikörper gegen humanes cd39 und ihre verwendung
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
WO2012101125A1 (en) 2011-01-24 2012-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Specific antibodies against human cxcl4 and uses thereof
US9315566B2 (en) 2011-01-24 2016-04-19 National University Of Singapore Pathogenic mycobacteria-derived mannose-capped lipoarabinomannan antigen binding proteins
WO2012113813A1 (en) 2011-02-23 2012-08-30 F. Hoffmann-La Roche Ag Antibodies against human il33r and uses thereof
US20130344074A1 (en) 2011-03-16 2013-12-26 Sanofi Uses of a dual v region antibody-like protein
ES2612914T3 (es) 2011-03-31 2017-05-19 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra Icos y usos de los mismos
CN103619881B (zh) 2011-04-07 2017-07-28 安姆根有限公司 新的egfr结合蛋白
EP3536708A1 (de) 2011-04-19 2019-09-11 Pfizer Inc Kombinationen aus anti-4-1bb-antikörpern und adcc-induzierenden antikörpern zur behandlung von krebs
RS58326B1 (sr) 2011-05-04 2019-03-29 Rhizen Pharmaceuticals S A Nova jedinjenja kao modulatori proteinskih kinaza
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
WO2012158964A2 (en) 2011-05-18 2012-11-22 Eumederis Pharmaceuticals, Inc. Improved peptide pharmaceuticals for osteoporosis
KR102255479B1 (ko) 2011-05-18 2021-05-24 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 제약
WO2012156532A1 (en) 2011-05-19 2012-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human-her3 antibodies and uses thereof
EP3808378A1 (de) 2011-05-27 2021-04-21 Baxalta GmbH Therapeutische proteine mit erhöhter halbwertzeit und verfahren zur herstellung davon
SI2714735T1 (sl) 2011-06-03 2021-12-31 Xoma Technology Ltd. Protitelesa, specifična za TGF-beta
ES2682249T3 (es) 2011-06-10 2018-09-19 Baxalta GmbH Tratamiento de una enfermedad de la coagulación mediante la administración de VWF recombinante
JP6005736B2 (ja) 2011-06-13 2016-10-12 ニューメディシンズ，インコーポレーテッド Ｉｌ−１２を用いる皮膚損傷の軽減
US9045526B2 (en) 2011-06-23 2015-06-02 The Regents Of The University Of Michigan Compound and method for modulating opioid receptor activity
EP2543679A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
EP2543677A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
EP2543678A1 (de) 2011-07-08 2013-01-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Antikörper zur Behandlung und Vorbeugung von Thrombose
EP2734546A1 (de) 2011-07-18 2014-05-28 Amgen Inc. Apelinantigen-bindende proteine und verwendungen davon
US20140234330A1 (en) 2011-07-22 2014-08-21 Amgen Inc. Il-17 receptor a is required for il-17c biology
WO2013022855A1 (en) 2011-08-05 2013-02-14 Xencor, Inc. Antibodies with modified isoelectric points and immunofiltering
EP3348575A1 (de) 2011-08-16 2018-07-18 Emory University Jaml-spezifische bindungsmittel, antikörper und verwendungen davon
WO2013025944A1 (en) 2011-08-17 2013-02-21 Genentech, Inc. Inhibition of angiogenesis in refractory tumors
AU2012301769B2 (en) 2011-08-31 2016-05-19 Amgen Inc. FGF21 for use in treating type 1 diabetes
CA2847698C (en) 2011-09-14 2020-09-01 Northwestern University Nanoconjugates able to cross the blood-brain barrier
JP6251678B2 (ja) 2011-09-22 2017-12-20 アムジエン・インコーポレーテツド Ｃｄ２７ｌ抗原結合タンパク質
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
AU2012323287B2 (en) 2011-10-10 2018-02-01 Xencor, Inc. A method for purifying antibodies
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
US20130095065A1 (en) 2011-10-13 2013-04-18 Aerpio Therapeutics, Inc. Methods for Treating Vascular Leak Syndrome and Cancer
JP2014532072A (ja) 2011-10-13 2014-12-04 エアピオ セラピューティックス， インコーポレイテッド 眼疾患の治療
JP2015504038A (ja) 2011-10-31 2015-02-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 低減した免疫原性を有するフィブロネクチン結合ドメイン
EP3536710A1 (de) 2011-11-16 2019-09-11 Boehringer Ingelheim International GmbH Anti il-36r-antikörper
JP2015501639A (ja) 2011-11-23 2015-01-19 アイジェニカ バイオセラピューティクス インコーポレイテッド 抗ｃｄ９８抗体およびその使用方法
CA2853204A1 (en) 2011-12-16 2013-06-20 Kalos Therapeutics, Inc. Methods and uses of anp (atrial natriuretic peptide), bnp (brain natriuretic peptide) and cnp (c-type natriuretic peptide)-related peptides and derivatives thereof for treatment of retinal disorders and diseases
EP2793944A4 (de) 2011-12-23 2015-09-02 Nicholas B Lydon Immunoglobuline und varianten gegen pathogene mikroben
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
EP2804620A4 (de) 2012-01-18 2016-04-13 Neumedicines Inc Il-12 für strahlenschutz und strahlungsbedingte toxizitätsabschwächung
KR101855242B1 (ko) 2012-01-26 2018-05-09 크리스토퍼 제이. 소레스 펩타이드 호르몬의 칼시토닌 cgrp 패밀리의 펩타이드 길항제 및 그의 용도
AP2014007875A0 (en) 2012-03-05 2014-08-31 Gilead Calistoga Llc Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
EP3626254A1 (de) 2012-03-16 2020-03-25 University Health Network Lösliches toso protein und dessen verwendung zur behandlung von autoimmunerkrankungen
SI2827883T1 (sl) 2012-03-21 2019-08-30 Baxalta GmbH Inhibitorji TFPI in postopki uporabe
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
WO2013149219A2 (en) 2012-03-30 2013-10-03 Sorrento Therapeutics Inc. Fully human antibodies that bind to vegfr2
MX359888B (es) 2012-03-30 2018-10-15 Rhizen Pharmaceuticals Sa Novedosos compuestos de 3h-imidazo [4,5-b] piridina 3,5-disubstituida y 3h- [1,2,3] triazolo [4,5-b] piridina 3,5-disubstituida como moduladores de c-met proteina cinasas.
WO2013151649A1 (en) 2012-04-04 2013-10-10 Sialix Inc Glycan-interacting compounds
US10385395B2 (en) 2012-04-11 2019-08-20 The Regents Of The University Of California Diagnostic tools for response to 6-thiopurine therapy
GB2516388A (en) 2012-04-16 2015-01-21 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
EA039663B1 (ru) 2012-05-03 2022-02-24 Амген Инк. Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств
US11078265B2 (en) 2012-05-03 2021-08-03 Boehringer Ingelheim International Gmbh Anti-IL-23 antibodies
EP2847219A1 (de) 2012-05-07 2015-03-18 Amgen Inc. Anti-erythropoietin-antikörper
CA2873511A1 (en) 2012-05-17 2013-11-21 Ra Pharmaceuticals, Inc. Peptide and peptidomimetic inhibitors
AR091069A1 (es) 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
CN115093480A (zh) 2012-05-31 2022-09-23 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
WO2013188448A2 (en) 2012-06-11 2013-12-19 Amgen Inc. Dual receptor antagonistic antigen-binding proteins and uses thereof
JP6429771B2 (ja) 2012-06-21 2018-11-28 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． ｃ−Ｍｅｔに結合する抗原結合タンパク質
JP6438391B2 (ja) 2012-06-22 2018-12-12 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｃｃｒ２に結合する抗原結合タンパク質
US9676847B2 (en) 2012-06-25 2017-06-13 Orega Biotech IL-17 antagonist antibodies
US20140004121A1 (en) 2012-06-27 2014-01-02 Amgen Inc. Anti-mesothelin binding proteins
DK2877490T3 (en) 2012-06-27 2018-12-17 Univ Princeton SPLIT INTEINS, CONJUGATES AND APPLICATIONS THEREOF
US9873739B2 (en) 2012-08-01 2018-01-23 Ikaika Therapeutics, Llc Mitigating tissue damage and fibrosis via latent transforming growth factor beta binding protein (LTBP4)
ES2771324T3 (es) 2012-08-03 2020-07-06 Dana Farber Cancer Inst Inc Usos médicos de agentes que modulan la activación de las células inmunitarias y métodos de detección correspondientes
US9695247B2 (en) 2012-09-03 2017-07-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies directed against ICOS for treating graft-versus-host disease
US11365229B2 (en) 2012-09-10 2022-06-21 Xencor, Inc. Methods of treating neurological diseases
TWI595007B (zh) 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗ｍｃａｍ抗體及相關使用方法
AU2013329311A1 (en) 2012-10-09 2015-04-30 Igenica Biotherapeutics, Inc. Anti-C16orf54 antibodies and methods of use thereof
KR102213907B1 (ko) 2012-11-20 2021-02-09 메더리스 다이어비티즈, 엘엘씨 인슐린 저항성에 대한 개선된 펩티드 약제
DK2922877T3 (da) 2012-11-20 2019-01-02 Eumederis Pharmaceuticals Inc Forbedrede peptidlægemidler
TWI664192B (zh) 2012-11-20 2019-07-01 法商賽諾菲公司 抗ｃｅａｃａｍ５抗體及其用途
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
EA201690004A1 (ru) 2012-12-27 2016-07-29 Санофи Антитела против lamp1 и конъюгаты антитела и лекарственного средства, а также их применение
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
WO2014110601A1 (en) 2013-01-14 2014-07-17 Xencor, Inc. Novel heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
US9738722B2 (en) 2013-01-15 2017-08-22 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US9920121B2 (en) 2013-01-25 2018-03-20 Amgen Inc. Antibodies targeting CDH19 for melanoma
KR20150136061A (ko) 2013-02-01 2015-12-04 산타 마리아 바이오테라퓨틱스, 인코포레이티드 대상에 항-액티빈-a 화합물의 투여
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
JOP20140087B1 (ar) 2013-03-13 2021-08-17 Amgen Inc بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
US9260527B2 (en) 2013-03-15 2016-02-16 Sdix, Llc Anti-human CXCR4 antibodies and methods of making same
EP3421495A3 (de) 2013-03-15 2019-05-15 Xencor, Inc. Modulation von t-zellen mit bispezifischen antikörpern und fc-fusionen
ES2759061T3 (es) 2013-03-15 2020-05-07 Biomolecular Holdings Llc Inmunoglobulina híbrida que contiene unión no peptidílica
WO2014140358A1 (en) 2013-03-15 2014-09-18 Amgen Research (Munich) Gmbh Single chain binding molecules comprising n-terminal abp
SG10201808523RA (en) 2013-03-15 2018-11-29 Genentech Inc Il-22 polypeptides and il-22 fc fusion proteins and methods of use
EP3587448B1 (de) 2013-03-15 2021-05-19 Xencor, Inc. Heterodimere proteine
KR102218494B1 (ko) 2013-03-15 2021-02-19 인트린식 라이프사이언시스, 엘엘씨 항-헵시딘 항체 및 그의 용도
EP2970446A1 (de) 2013-03-15 2016-01-20 Amgen Research (Munich) GmbH Antikörperkonstrukte für influenza m2 und cd3
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
PL2981822T3 (pl) 2013-05-06 2021-07-12 Scholar Rock, Inc. Kompozycje i sposoby modulacji czynnika wzrostu
WO2014183885A1 (en) 2013-05-17 2014-11-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of the btla/hvem interaction for use in therapy
PT3004167T (pt) 2013-05-30 2018-11-13 Kiniksa Pharmaceuticals Ltd Proteínas de ligação ao antigénio do recetor da oncostatina m
CN105683217B (zh) 2013-05-31 2019-12-10 索伦托治疗有限公司 与pd-1结合的抗原结合蛋白
TWI482782B (zh) * 2013-05-31 2015-05-01 Univ Nat Chiao Tung 架接抗體之雙乳化核殼奈米結構
AU2013396206B2 (en) 2013-06-28 2019-11-14 Amgen Inc. Methods for treating homozygous familial hypercholesterolemia
TWI688401B (zh) 2013-09-13 2020-03-21 美商安進公司 用於治療骨髓性白血病的表觀遺傳因子與靶向ｃｄ３３及ｃｄ３之雙特異性化合物的組合
EP3757130A1 (de) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Verfahren zur behandlung von blutkrebs
CA2924386C (en) 2013-10-04 2021-07-20 F. Hoffmann-La Roche Ag Antibodies specifically binding to her3
EP3055331B1 (de) 2013-10-11 2021-02-17 Oxford Bio Therapeutics Limited Konjugierte antikörper gegen ly75 zur behandlung von krebs
EP3057605A1 (de) 2013-10-18 2016-08-24 Novartis AG Verfahren zur behandlung von diabetes und verwandten erkrankungen
EP3063317B1 (de) 2013-10-28 2020-06-03 DOTS Technology Corp. Allergennachweis
PL3063275T3 (pl) 2013-10-31 2020-03-31 Resolve Therapeutics, Llc Terapeutyczne fuzje nukleaza-albumina i sposoby
CN104623637A (zh) 2013-11-07 2015-05-20 健能隆医药技术（上海）有限公司 Il-22二聚体在制备静脉注射药物中的应用
US9708327B2 (en) 2013-12-20 2017-07-18 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
MX2016008259A (es) 2013-12-20 2016-10-13 Gilead Calistoga Llc Metodo de proceso para inhibidores de fosfatidilinositol 3-cinasa.
AU2015204446A1 (en) 2014-01-13 2016-07-14 Valerion Therapeutics, Llc Internalizing moieties
EP3738981A1 (de) 2014-01-24 2020-11-18 NGM Biopharmaceuticals, Inc. Beta-klotho 2 bindende antikörper und verfahren zur verwendung davon
EP3099715B1 (de) 2014-01-31 2020-11-18 Boehringer Ingelheim International GmbH Neue anti-baff antikörper
EP3107935B1 (de) 2014-02-20 2020-06-24 Allergan, Inc. Antikörper der komplementkomponente c5
CA2939586A1 (en) 2014-02-27 2015-09-03 Allergan, Inc. Complement factor bb antibodies
JP6538707B2 (ja) 2014-03-07 2019-07-03 ユニバーシティ ヘルス ネットワーク 免疫応答を調節するための方法及び組成物
NZ724904A (en) 2014-03-14 2023-04-28 Biomolecular Holdings Llc Hybrid immunoglobulin containing non-peptidyl linkage
CR20160506A (es) 2014-03-28 2017-03-10 Xencor Inc Anticuerpos biespecíficos que se unen a cd38 y cd3
FR3020063A1 (fr) 2014-04-16 2015-10-23 Gamamabs Pharma Anticorps humain anti-her4
US10544231B2 (en) 2014-04-16 2020-01-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies for the prevention or the treatment of bleeding episodes
CA2949701C (en) 2014-05-28 2023-12-12 Mederis Diabetes, Llc Improved peptide pharmaceuticals for insulin resistance
PT3148581T (pt) 2014-05-30 2020-01-06 Henlix Biotech Co Ltd Anticorpos antirrecetor do fator de crescimento epidérmico (egfr)
CA2949985C (en) 2014-06-12 2023-10-17 Ra Pharmaceuticals, Inc. Modulation of complement activity
MX2016016530A (es) 2014-06-13 2017-03-27 Gilead Sciences Inc Inhibidores de fosfatidilinositol 3-quinasa.
US10562946B2 (en) 2014-06-20 2020-02-18 Genentech, Inc. Chagasin-based scaffold compositions, methods, and uses
CA2956471A1 (en) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Optimized cross-species specific bispecific single chain antibody constructs
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
US20170275373A1 (en) 2014-07-31 2017-09-28 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
WO2016028523A2 (en) 2014-08-22 2016-02-25 Sorrento Therapeutics, Inc. Antigen binding proteins that bind cxcr3
EP3575316A1 (de) 2014-08-27 2019-12-04 Amgen, Inc Varianten des gewebehemmers von metalloproteinase-typ-3 (timp-3), zusammensetzungen und verfahren
US10323088B2 (en) 2014-09-22 2019-06-18 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
CN115920007A (zh) 2014-10-24 2023-04-07 阿斯利康(瑞典)有限公司 组合
US20170306046A1 (en) 2014-11-12 2017-10-26 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US9879087B2 (en) 2014-11-12 2018-01-30 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
CN107106493A (zh) 2014-11-21 2017-08-29 西北大学 球形核酸纳米颗粒缀合物的序列特异性细胞摄取
CA2968878A1 (en) 2014-11-26 2016-06-02 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
DK3223845T3 (da) 2014-11-26 2021-08-16 Xencor Inc Heterodimere antistoffer, der binder cd3 og cd20
CN111018987B (zh) 2014-12-05 2023-11-21 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其应用
AU2015360903B2 (en) 2014-12-08 2021-03-25 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMB and anti-PD-1 agents
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
EP3237449A2 (de) 2014-12-22 2017-11-01 Xencor, Inc. Trispezifische antikörper
ES2881484T3 (es) 2014-12-22 2021-11-29 Pd 1 Acquisition Group Llc Anticuerpos anti-PD-1
CN104524169A (zh) * 2014-12-25 2015-04-22 庞凤梅 一种治疗老年性喘咳的中药制剂
PL3240801T3 (pl) 2014-12-31 2021-06-14 Checkmate Pharmaceuticals, Inc. Skojarzona immunoterapia nowotworów
CN114230667A (zh) 2015-01-23 2022-03-25 赛诺菲 抗cd3抗体、抗cd123抗体和与cd3和/或cd123特异性结合的双特异性抗体
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
EP3271388A1 (de) 2015-02-09 2018-01-24 INSERM - Institut National de la Santé et de la Recherche Médicale Spezifische antikörper gegen glykoprotein (gp) des ebolavirus und verwendungen zur behandlung und diagnose von ebolavirusinfektion
WO2016130986A1 (en) 2015-02-13 2016-08-18 Sorrento Therapeutics, Inc. Antibody therapeutics that bind ctla4
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
US10059774B2 (en) 2015-04-08 2018-08-28 Sorrento Therapeutics, Inc. Antibody therapeutics that bind CD38
UA126270C2 (uk) 2015-04-10 2022-09-14 Емджен Інк. Мутеїни інтерлейкіну-2 для росту регуляторних t-клітин
SG10201909308XA (en) 2015-04-17 2019-11-28 Amgen Res Munich Gmbh Bispecific antibody constructs for cdh3 and cd3
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
EP3307253A4 (de) 2015-06-12 2018-11-21 Georgia State University Research Foundation, Inc. Zusammensetzungen und verfahren zur behandlung von opioid-toleranz
CN107849126B (zh) 2015-07-29 2022-04-08 阿勒根公司 仅有重链的抗ang-2抗体
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TW202346349A (zh) 2015-07-31 2023-12-01 德商安美基研究（慕尼黑）公司 Dll3及cd3抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
JP2018523673A (ja) 2015-08-14 2018-08-23 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Ｐｄｇｆに対する重鎖のみ抗体
HUE063528T2 (hu) 2015-09-01 2024-01-28 Boehringer Ingelheim Int Anti-CD40 antitestek alkalmazása lupus nephritis kezelésére
TWI799366B (zh) 2015-09-15 2023-04-21 美商建南德克公司 胱胺酸結骨架平臺
JP7002446B2 (ja) 2015-09-21 2022-03-04 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
JP2018535655A (ja) 2015-09-29 2018-12-06 アムジエン・インコーポレーテツド Ａｓｇｒ阻害剤
CA2997963A1 (en) 2015-09-29 2017-04-06 Celgene Corporation Pd-1 binding proteins and methods of use thereof
CA3000697A1 (en) 2015-10-01 2017-04-06 Amgen Inc. Treatment of bile acid disorders
EP3359575B1 (de) 2015-10-09 2020-07-22 Florida State University Research Foundation, Inc. Für 4,6-diamino-5-(formylamino)-pyrimidin spezifische antikörper und verwendungen davon
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
CN116217729A (zh) 2015-11-12 2023-06-06 思进公司 聚糖相互作用化合物及使用方法
KR20180093010A (ko) 2015-12-04 2018-08-20 더 리전트 오브 더 유니버시티 오브 캘리포니아 새로운 암 치료용 항체
CN108699136B (zh) 2015-12-07 2022-03-18 Xencor股份有限公司 结合cd3和psma的异二聚抗体
KR20180094913A (ko) 2015-12-16 2018-08-24 라 파마슈티컬스 인코포레이티드 보체 활성의 조절인자
JP6883590B2 (ja) 2016-01-29 2021-06-09 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｐｄ−ｌ１に結合する抗原結合性タンパク質
EP3411404B1 (de) 2016-02-03 2022-11-09 Amgen Research (Munich) GmbH Psma- und cd3-bispezifische t-zellaktivierende antikörperkonstrukte
EA039859B1 (ru) 2016-02-03 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
BR112018015715A2 (pt) 2016-02-03 2019-02-05 Amgen Inc construtos de anticorpo de engate de célula t biespecífica bcma e cd3
CN109071669A (zh) 2016-03-07 2018-12-21 查尔斯顿制药有限责任公司 抗核仁素抗体
EP3442562B1 (de) 2016-04-15 2022-09-21 Evive Biotechnology (Shanghai) Ltd Ein il-22-dimer zur verwendung in der behandlung der nekrotisierenden enterokolitis
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
WO2017189988A1 (en) 2016-04-29 2017-11-02 Araim Pharmaceuticals, Inc. Tissue protective peptides for preventing and treating diseases and disorders associated with tissue damage
EP3280725B1 (de) 2016-05-04 2020-08-26 Amgen Inc. Interleukin-2-muteine zur expansion von t-regulatorischen zellen
TWI826351B (zh) 2016-05-31 2023-12-21 大陸商鴻運華寧（杭州）生物醫藥有限公司 Ｒ抗體,其藥物組合物及其應用
WO2017218707A2 (en) 2016-06-14 2017-12-21 Xencor, Inc. Bispecific checkpoint inhibitor antibodies
CN116063545A (zh) 2016-06-28 2023-05-05 Xencor股份有限公司 结合生长抑素受体2的异源二聚抗体
CN117330747A (zh) 2016-07-15 2024-01-02 武田药品工业株式会社 用于评估对于成浆细胞和浆细胞耗竭性疗法的应答的方法和材料
TWI790206B (zh) 2016-07-18 2023-01-21 法商賽諾菲公司 特異性結合至ｃｄ３和ｃｄ１２３的雙特異性抗體樣結合蛋白
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
KR102657418B1 (ko) 2016-09-02 2024-04-15 크리스토퍼 제이 소레스 신경 보호 및 신경 질환에서의 cgrp 수용체 길항제의 용도
EP3509616A1 (de) 2016-09-09 2019-07-17 H. Hoffnabb-La Roche Ag Selektive peptidinhibitoren des frizzled
RU2752832C2 (ru) 2016-09-16 2021-08-09 Шанхай Хенлиус Байотек, Инк. Анти-pd-1 антитела
JP2019534859A (ja) 2016-09-19 2019-12-05 セルジーン コーポレイション Ｐｄ−１結合タンパク質を使用して白斑を治療する方法
US10751414B2 (en) 2016-09-19 2020-08-25 Celgene Corporation Methods of treating psoriasis using PD-1 binding antibodies
EP3523330A1 (de) 2016-10-04 2019-08-14 Fairbanks Pharmaceuticals, Inc. Anti-fstl3-antikörper und verwendungen davon
EP3526241A1 (de) 2016-10-14 2019-08-21 Xencor, Inc. Il15/il15r-heterodimere fc-fusionsproteine
US11548935B2 (en) 2016-10-14 2023-01-10 Neomatrix Therapeutics Inc. Peptides derived from fibronectin with improved bioactivity and reduced susceptibility to neutrophil elastase degradation
US11286295B2 (en) 2016-10-20 2022-03-29 Sanofi Anti-CHIKV monoclonal antibodies directed against the E2 structural protein
US11414482B2 (en) 2016-11-08 2022-08-16 University Of Miami Anti-secretogranin III (SCG3) antibodies and uses thereof
EP3541847A4 (de) 2016-11-17 2020-07-08 Seattle Genetics, Inc. Glycaninteragierende verbindungen und verfahren zur verwendung
JP7301741B2 (ja) 2016-12-07 2023-07-03 ラ ファーマシューティカルズ インコーポレイテッド 補体活性のモジュレータ
EP3608333A1 (de) 2016-12-07 2020-02-12 Molecular Templates, Inc. Shiga-toxin-a-untereinheit-effektor-polypeptide, shiga-toxin-effektor-gerüste und auf zellen abzoelende moleküle zur stellenspezifischen konjugation
EP3571216A4 (de) 2017-01-19 2020-11-04 The United States of America, as represented by the Secretary, Department of Health and Human Services Apoc-ii-mimetische peptide
JOP20190189A1 (ar) 2017-02-02 2019-08-01 Amgen Res Munich Gmbh تركيبة صيدلانية ذات درجة حموضة منخفضة تتضمن بنيات جسم مضاد يستهدف الخلية t
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP3589319A4 (de) 2017-03-03 2021-07-14 Seagen Inc. Glycaninteragierende verbindungen und verfahren zur verwendung
GB201703876D0 (en) 2017-03-10 2017-04-26 Berlin-Chemie Ag Pharmaceutical combinations
JP7308150B2 (ja) 2017-03-16 2023-07-13 イナート・ファルマ・ソシエテ・アノニム 癌を処置するための組成物及び方法
US20180273627A1 (en) 2017-03-27 2018-09-27 Boehringer Ingelheim International Gmbh Anti il-36r antibodies combination therapy
US10729741B2 (en) 2017-03-27 2020-08-04 Neomatrix Therapeutics Inc. Methods of treating burns with i.v. cP12 in a window from 2 to 6 hours after injury
EP3615569A1 (de) 2017-04-25 2020-03-04 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
AU2018261951A1 (en) 2017-05-05 2019-10-31 Amgen Inc. Pharmaceutical composition comprising bispecific antibody constructs for improved storage and administration
US10793634B2 (en) 2017-06-09 2020-10-06 Boehringer Ingelheim International Gmbh Anti-TrkB antibodies
CN111132733A (zh) 2017-06-30 2020-05-08 Xencor股份有限公司 含有IL-15/IL-15Rα和抗原结合结构域的靶向异源二聚体Fc融合蛋白
WO2019010497A1 (en) 2017-07-07 2019-01-10 Baxalta Incorporated TREATMENT OF GASTROINTESTINAL BLEEDING IN PATIENTS WITH A SEVERE FORM OF VON WILLEBRAND'S DISEASE BY RECOMBINANT VWF ADMINISTRATION
EP3648787A1 (de) 2017-07-07 2020-05-13 Baxalta Incorporated Behandlung von patienten mit schwerer von-willebrand-krankheit mit elektivem eingriff bei verabreichung von rekombinantem vwf
WO2019018629A1 (en) 2017-07-19 2019-01-24 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
SG11202001311VA (en) 2017-08-22 2020-03-30 Sanabio Llc Soluble interferon receptors and uses thereof
KR20200074127A (ko) 2017-11-02 2020-06-24 옥스포드 바이오테라퓨틱스 리미티드 항체 및 사용 방법
US11312770B2 (en) 2017-11-08 2022-04-26 Xencor, Inc. Bispecific and monospecific antibodies using novel anti-PD-1 sequences
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
AU2018369639A1 (en) 2017-11-14 2020-04-23 Arcellx, Inc. D-domain containing polypeptides and uses thereof
US20210163592A1 (en) 2017-12-11 2021-06-03 Amgen Inc Continuous manufacturing process for bispecific antibody products
CA3086199A1 (en) 2017-12-19 2019-06-27 Xencor, Inc. Engineered il-2 fc fusion proteins
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
EP3732193A1 (de) 2017-12-29 2020-11-04 Alector LLC Anti-tmem106b-antikörper und verfahren zu ihrer verwendung
JP2021509892A (ja) 2018-01-03 2021-04-08 メデリス ダイアビーティーズ，エルエルシー Ｎａｓｈおよびその他障害の処置用の改善されたペプチド薬剤
SG11202006259SA (en) 2018-01-26 2020-08-28 Genentech Inc Il-22 fc fusion proteins and methods of use
HUE060435T2 (hu) 2018-01-26 2023-03-28 Hoffmann La Roche IL-22 Fc készítmények és alkalmazásukra szolgáló eljárások
JP7268038B2 (ja) 2018-01-31 2023-05-02 アレクトル エルエルシー 抗ｍｓ４ａ４ａ抗体及びその使用方法
SG11202007702UA (en) 2018-02-14 2020-09-29 Viela Bio Inc Antibodies to feline mcdonough sarcoma (fms)-like tyrosine kinase 3 receptor ligand (flt3l) and uses thereof for treating autoimmune and inflammatory diseases
JP2021514354A (ja) 2018-02-21 2021-06-10 ジェネンテック， インコーポレイテッド ＩＬ−２２Ｆｃ融合タンパク質による治療のための投与
CN112166123B (zh) 2018-03-14 2022-09-30 北京轩义医药科技有限公司 抗紧密连接蛋白18.2抗体
CN117126279A (zh) 2018-03-20 2023-11-28 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
BR112020019057A2 (pt) 2018-03-21 2020-12-29 Baxalta Incorporated Método para obter uma composição, e, composição farmacêutica.
US10982006B2 (en) 2018-04-04 2021-04-20 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
CN112334485A (zh) 2018-04-06 2021-02-05 百进生物科技公司 抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
CN110357959B (zh) 2018-04-10 2023-02-28 鸿运华宁（杭州）生物医药有限公司 Gcgr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
WO2019204655A1 (en) 2018-04-18 2019-10-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
KR20210010862A (ko) 2018-04-18 2021-01-28 젠코어 인코포레이티드 IL-15/IL-15Rα Fc-융합 단백질 및 PD-1 항원 결합 도메인을 함유하는 PD-1 표적화 이종이량체 융합 단백질 및 이의 용도
MX2020011468A (es) 2018-04-30 2021-02-09 Medimmune Ltd Conjugados para detectar selectivamente y eliminar agregados.
AR114436A1 (es) 2018-04-30 2020-09-02 Takeda Pharmaceuticals Co Proteínas de unión al receptor de cannabinoides tipo 1 (cb1) y usos de las mismas
EP3788071A1 (de) 2018-05-02 2021-03-10 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Antikörper und verfahren zur diagnose, prävention und behandlung von epstein-barr-virusinfektion
US11319373B2 (en) 2018-05-25 2022-05-03 Alector Llc Anti-SIRPA antibodies and methods of use thereof
CN110655577A (zh) 2018-06-13 2020-01-07 鸿运华宁（杭州）生物医药有限公司 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
GB201809746D0 (en) 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
CA3099893A1 (en) 2018-06-18 2019-12-26 Innate Pharma Compositions and methods for treating cancer
WO2020006347A1 (en) 2018-06-29 2020-01-02 Boehringer Ingelheim International Gmbh Anti-cd40 antibodies for use in treating autoimmune disease
KR20210025614A (ko) 2018-06-29 2021-03-09 알렉터 엘엘씨 항-sirp-베타1 항체 및 그의 사용 방법
TW202019473A (zh) 2018-07-02 2020-06-01 美商安進公司 抗steap1抗原結合蛋白
WO2020014617A1 (en) 2018-07-13 2020-01-16 Alector Llc Anti-sortilin antibodies and methods of use thereof
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
MX2021001221A (es) 2018-07-30 2021-06-23 Amgen Res Munich Gmbh Administración prolongada de un constructo de anticuerpo biespecífico que se une a cd33 y cd3.
WO2020025792A1 (en) 2018-08-03 2020-02-06 Amgen Research (Munich) Gmbh Antibody constructs for cldn18.2 and cd3
MA53493A (fr) 2018-08-31 2021-07-07 Alx Oncology Inc Polypeptides leurres
WO2020068653A1 (en) 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
EP3856343A1 (de) 2018-09-25 2021-08-04 Biolegend, Inc. Anti-tlr9-mittel und zusammensetzungen sowie verfahren zu ihrer herstellung und verwendung
WO2020065594A1 (en) 2018-09-28 2020-04-02 Kyowa Kirin Co., Ltd. Il-36 antibodies and uses thereof
JP2022503959A (ja) 2018-10-03 2022-01-12 ゼンコア インコーポレイテッド Ｉｌ－１２ヘテロ二量体ｆｃ－融合タンパク質
AU2019356564A1 (en) 2018-10-11 2021-04-29 Amgen Inc. Downstream processing of bispecific antibody constructs
JP2022516635A (ja) 2019-01-04 2022-03-01 リゾルブ セラピューティクス， エルエルシー ヌクレアーゼ融合タンパク質によるシェーグレン病の処置
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
EA202192140A1 (ru) 2019-02-01 2021-12-15 Такеда Фармасьютикал Компани Лимитед СПОСОБЫ ПРОФИЛАКТИЧЕСКОГО ЛЕЧЕНИЯ РЕКОМБИНАНТНЫМ ФВ (рФВ)
EP3693023A1 (de) 2019-02-11 2020-08-12 Sanofi Verwendung von anti-ceacam5-immunkonjugaten zur behandlung von lungenkrebs
MX2021009514A (es) 2019-02-07 2021-11-04 Sanofi Sa Uso de inmunoconjugados anti-ceacam5 para el tratamiento del cancer de pulmon.
EP3930850A1 (de) 2019-03-01 2022-01-05 Xencor, Inc. Enpp3 und cd3 bindende heterodimere antikörper
AU2020248645A1 (en) 2019-03-27 2021-10-28 Tigatx, Inc. Engineered IgA antibodies and methods of use
JP2022528721A (ja) 2019-04-09 2022-06-15 アブクロ，インク． キラー細胞レクチン様受容体サブファミリーｇメンバー１（ｋｌｒｇ１）除去抗体
EP4283295A3 (de) 2019-04-30 2024-03-06 Gigagen, Inc. Rekombinante polyklonale proteine und verfahren zur verwendung davon
PE20220287A1 (es) 2019-05-09 2022-02-25 Boehringer Ingelheim Int Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
AU2020290573A1 (en) 2019-06-13 2021-11-04 Amgen Inc. Automated biomass-based perfusion control in the manufacturing of biologics
TW202115112A (zh) 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體
US20220372137A1 (en) 2019-07-03 2022-11-24 Oxford Biotherapeutics Ltd Antibodies and methods of use
CN112239507A (zh) 2019-07-17 2021-01-19 鸿运华宁（杭州）生物医药有限公司 ETA抗体与TGF-β Trap的融合蛋白质，以及其药物组合物和应用
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
KR20220058540A (ko) 2019-07-31 2022-05-09 알렉터 엘엘씨 항-ms4a4a 항체 및 이의 사용 방법
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
CN114555634A (zh) 2019-08-13 2022-05-27 美国安进公司 用于扩增调节性t细胞的白介素-2突变蛋白
MX2022002981A (es) 2019-09-10 2022-04-06 Amgen Inc Metodo de purificacion para polipeptidos de union a antigeno biespecificos con capacidad de union dinamica de captura de proteina l mejorada.
JP2022547556A (ja) 2019-09-11 2022-11-14 武田薬品工業株式会社 フォン・ヴィレブランド因子と補体ｃ１ｑの複合体に関連する治療法
CN112521501A (zh) 2019-09-18 2021-03-19 鸿运华宁（杭州）生物医药有限公司 Gipr抗体及其与glp-1的融合蛋白质，以及其药物组合物和应用
TW202126685A (zh) 2019-09-24 2021-07-16 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
EP4055031A2 (de) 2019-11-04 2022-09-14 Alector LLC Siglec-9 ecd-fusionsmoleküle und verfahren zur verwendung davon
WO2021097344A1 (en) 2019-11-13 2021-05-20 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
US20230242655A1 (en) 2019-12-03 2023-08-03 Evotec International Gmbh Interferon-associated antigen binding proteins and uses thereof
CN115052626A (zh) 2019-12-03 2022-09-13 埃沃特克国际有限责任公司 用于治疗乙型肝炎感染的干扰素相关抗原结合蛋白
WO2021113596A2 (en) 2019-12-05 2021-06-10 Sorrento Therapeutics, Inc. Compositions and methods comprising an anti-cd47 antibody in combination with a tumor targeting antibody
CR20220329A (es) 2019-12-13 2022-11-23 Alector Llc Anticuerpos anti–mertk y metodos de uso de los mismos
CN114867749A (zh) 2019-12-17 2022-08-05 安进公司 用于疗法中的双重白介素-2/tnf受体激动剂
US20230132241A1 (en) 2020-01-15 2023-04-27 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding prame
CN115427447A (zh) 2020-01-17 2022-12-02 百进生物科技公司 抗tlr7药剂和组合物以及制备和使用其的方法
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
AU2021216945A1 (en) 2020-02-04 2022-09-01 Takeda Pharmaceutical Company Limited Treatment of menorrhagia in patients with severe von Willebrand Disease by administration of recombinant VWF
CN115485300A (zh) 2020-02-26 2022-12-16 索伦托药业有限公司 具有通用掩蔽部分的可活化的抗原结合蛋白
TW202200615A (zh) 2020-03-12 2022-01-01 美商安進公司 用於治療和預防患者的crs之方法
WO2021195089A1 (en) 2020-03-23 2021-09-30 Sorrento Therapeutics, Inc. Fc-coronavirus antigen fusion proteins, and nucleic acids, vectors, compositions and methods of use thereof
WO2021202590A1 (en) 2020-03-31 2021-10-07 Alector Llc Anti-mertk antibodies and methods of use thereof
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
WO2021211753A1 (en) 2020-04-15 2021-10-21 Voyager Therapeutics, Inc. Tau binding compounds
EP4138884A1 (de) 2020-04-20 2023-03-01 Sorrento Therapeutics, Inc. Pulmonale verabreichung von ace2-polypeptiden
US11919956B2 (en) 2020-05-14 2024-03-05 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (PSMA) and CD3
JP2023527293A (ja) 2020-05-19 2023-06-28 アムジエン・インコーポレーテツド Ｍａｇｅｂ２結合構築物
AU2021280232A1 (en) 2020-05-26 2022-12-15 Boehringer Ingelheim International Gmbh Anti-PD-1 antibodies
WO2021243320A2 (en) 2020-05-29 2021-12-02 Amgen Inc. Adverse effects-mitigating administration of a bispecific antibody construct binding to cd33 and cd3
CA3177152A1 (en) 2020-06-12 2021-12-16 David Scott Johnson Recombinant polyclonal proteins targeting covid-19 and methods of use thereof
EP4169949A1 (de) 2020-06-23 2023-04-26 Jiangsu Kanion Pharmaceutical Co., Ltd. Anti-cd38-antikörper und verwendung davon
CA3183034A1 (en) 2020-06-26 2021-12-30 Heyue Zhou Anti-pd1 antibodies and uses thereof
WO2022006153A1 (en) 2020-06-29 2022-01-06 Resolve Therapeutics, Llc Treatment of sjogren's syndrome with nuclease fusion proteins
WO2022031834A1 (en) 2020-08-05 2022-02-10 Gigagen, Inc. Recombinant polyclonal proteins targeting zika and methods of use thereof
MX2023002330A (es) 2020-09-04 2023-03-21 Merck Patent Gmbh Anticuerpos anti molecula de adhesion celular 5 relacionada con el antigeno carcinoembrionario (ceacam5) y conjugados y usos de los mismos.
EP4213939A1 (de) 2020-09-21 2023-07-26 Boehringer Ingelheim International GmbH Verwendung von anti-cd40-antikörpern zur behandlung von entzündlichen erkrankungen
US20220127344A1 (en) 2020-10-23 2022-04-28 Boehringer Ingelheim International Gmbh Anti-sema3a antibodies and their uses for treating a thrombotic disease of the retina
WO2022093641A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2a agents and compositions and methods for making and using the same
WO2022093640A1 (en) 2020-10-30 2022-05-05 BioLegend, Inc. Anti-nkg2c agents and compositions and methods for making and using the same
EP4240768A2 (de) 2020-11-06 2023-09-13 Amgen Inc. Multitargeting bispezifischer antigenbindender moleküle mit erhöhter selektivität
AR124019A1 (es) 2020-11-06 2023-02-01 Amgen Res Munich Gmbh Construcciones polipeptídicas que se unen a cd3
IL301926A (en) 2020-11-06 2023-06-01 Amgen Inc Antigen binding domain with reduced cleavage rate
AU2021374036A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
JP2023554382A (ja) 2020-12-16 2023-12-27 ボイジャー セラピューティクス インコーポレイテッド タウ結合化合物
WO2022147463A2 (en) 2020-12-31 2022-07-07 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof
WO2022159575A1 (en) 2021-01-20 2022-07-28 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
TW202246314A (zh) 2021-01-28 2022-12-01 美商特蘭治療公司 抗棘狀醣蛋白抗體及其治療用途
EP4288457A2 (de) 2021-02-05 2023-12-13 Boehringer Ingelheim International GmbH Anti-il1rap-antikörper
CN117157319A (zh) 2021-03-09 2023-12-01 Xencor股份有限公司 结合cd3和cldn6的异二聚抗体
WO2022192586A1 (en) 2021-03-10 2022-09-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
AU2022238571A1 (en) 2021-03-18 2023-09-14 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022197947A1 (en) 2021-03-18 2022-09-22 Alector Llc Anti-tmem106b antibodies and methods of use thereof
WO2022204274A1 (en) 2021-03-23 2022-09-29 Alector Llc Anti-tmem106b antibodies for treating and preventing coronavirus infections
JP2024515165A (ja) 2021-03-26 2024-04-05 アブクロ，インク． 抗ｋｌｒｇ１抗体
WO2022204529A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
CN115141276A (zh) 2021-03-31 2022-10-04 鸿运华宁（杭州）生物医药有限公司 一种能与人内皮素受体特异性结合的抗体及其在糖尿病肾病和慢性肾病治疗中的应用
WO2022212836A1 (en) 2021-04-01 2022-10-06 Pyxis Oncology, Inc. Gpnmb antibodies and methods of use
EP4314078A1 (de) 2021-04-02 2024-02-07 Amgen Inc. Mageb2-bindende konstrukte
CN117279947A (zh) 2021-05-06 2023-12-22 安进研发（慕尼黑）股份有限公司 用于在增殖性疾病中使用的靶向cd20和cd22的抗原结合分子
EP4347653A1 (de) 2021-06-04 2024-04-10 Boehringer Ingelheim International GmbH Anti-sirp-alpha-antikörper
WO2022261183A2 (en) 2021-06-08 2022-12-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
EP4351732A1 (de) 2021-06-09 2024-04-17 Evotec International GmbH Interferon-assoziierte antigenbindende proteine zur verwendung zur behandlung oder prävention von coronavirus-infektionen
EP4355783A1 (de) 2021-06-16 2024-04-24 Alector LLC Monovalente anti-mertk-antikörper und verfahren zur verwendung davon
WO2022266223A1 (en) 2021-06-16 2022-12-22 Alector Llc Bispecific anti-mertk and anti-pdl1 antibodies and methods of use thereof
AU2022320627A1 (en) 2021-07-26 2024-02-08 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
WO2023069919A1 (en) 2021-10-19 2023-04-27 Alector Llc Anti-cd300lb antibodies and methods of use thereof
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
TW202340241A (zh) 2021-12-02 2023-10-16 法商賽諾菲公司 Ｃｅａｃａｍ５ ａｄｃ－抗ｐｄ１／ｐｄ－ｌ１組合療法
TW202339804A (zh) 2021-12-02 2023-10-16 法商賽諾菲公司 在癌症療法中用於患者選擇的ｃｅａ測定
US20230257455A1 (en) 2021-12-22 2023-08-17 Cdr-Life Ag Anti-c3 antibodies and antigen-binding fragments thereof and their uses for treating eye or ocular diseases
US20230227545A1 (en) 2022-01-07 2023-07-20 Johnson & Johnson Enterprise Innovation Inc. Materials and methods of il-1beta binding proteins
WO2023172968A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Anti-gd2 antibodies, immunoconjugates and therapeutic uses thereof
WO2023170239A1 (en) 2022-03-09 2023-09-14 Merck Patent Gmbh Methods and tools for conjugation to antibodies
TW202346368A (zh) 2022-05-12 2023-12-01 德商安美基研究（慕尼黑）公司 具有增加的選擇性的多鏈多靶向性雙特異性抗原結合分子
WO2023240287A1 (en) 2022-06-10 2023-12-14 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
WO2023250388A1 (en) 2022-06-22 2023-12-28 Voyager Therapeutics, Inc. Tau binding compounds
WO2024013727A1 (en) 2022-07-15 2024-01-18 Janssen Biotech, Inc. Material and methods for improved bioengineered pairing of antigen-binding variable regions
WO2024020051A1 (en) 2022-07-19 2024-01-25 BioLegend, Inc. Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
WO2024026447A1 (en) 2022-07-29 2024-02-01 Alector Llc Anti-gpnmb antibodies and methods of use thereof
WO2024040114A2 (en) 2022-08-18 2024-02-22 BioLegend, Inc. Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
WO2024059675A2 (en) 2022-09-14 2024-03-21 Amgen Inc. Bispecific molecule stabilizing composition
WO2024081918A1 (en) 2022-10-14 2024-04-18 Talem Therapeutics Llc Anti-trkb/cd3 antibodies and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE343210B (de) * 1967-12-20 1972-03-06 Pharmacia Ab
US4167446A (en) * 1973-03-15 1979-09-11 Bayer Aktiengesellschaft Water soluble carrier-bound penicillinacylase
US3876501A (en) * 1973-05-17 1975-04-08 Baxter Laboratories Inc Binding enzymes to activated water-soluble carbohydrates
US3947352A (en) * 1974-05-31 1976-03-30 Pedro Cuatrecasas Polysaccharide matrices for use as adsorbents in affinity chromatography techniques
JPS54113492A (en) * 1978-02-24 1979-09-05 Sanyo Chem Ind Ltd Preparation of glucoprotein derivative
EP0067293B1 (de) * 1981-05-01 1986-06-25 Medical Research Institute of San Francisco Verfahren zur Isolierung von Alpha-1-antitrypsin
US4439358A (en) * 1982-06-17 1984-03-27 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US4379087A (en) * 1982-06-17 1983-04-05 Cutter Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
JPS5959629A (ja) * 1982-09-27 1984-04-05 Nippon Chem Res Kk 効力持続性組成物

Also Published As

Publication number Publication date
EP0147761B1 (de) 1990-08-29
ATE56025T1 (de) 1990-09-15
CA1242664A (en) 1988-10-04
ES8605826A1 (es) 1986-04-01
ES538807A0 (es) 1986-04-01
JPH0696541B2 (ja) 1994-11-30
US4496689A (en) 1985-01-29
EP0147761A2 (de) 1985-07-10
EP0147761A3 (en) 1986-07-30
JPS60178823A (ja) 1985-09-12

Similar Documents

Publication Publication Date Title
DE3483094D1 (de) Kovalent gebundener komplex eines alpha-1-proteinase inhibitors mit einem wasserloeslichen polymer.
DE69428268T2 (de) Verwendung von lokalanaesthetika zur herstellung eines arzneimittels zur behandlung von bronchialasthma
CA2213339A1 (en) Method of treating adenosine depletion
ATE231519T1 (de) Dinukleotide zur verwendung in der behandlung von lungenkrankheiten
ATE267607T1 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
DE69634776D1 (de) Verwendung eines r-nsaid als chemoschützendes mittel zur behandlung kolorektales krebs
HUT62798A (en) Process for producing pharmaceutical composition with slimming activity
DE69636343D1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ATE280496T1 (de) Verfahren zur behandlung von asthma mit o- desulfatisiertem heparin
ES8300260A1 (es) Procedimiento para la produccion de una venda para vendajes de sosten semirigido medicinales
MY106528A (en) Method of treating impotence.
NO840257L (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive (d1)-16-fenoksy- og 16-substituerte fenoksy-9-keto-prostatriensyre-derivater
DE3478749D1 (en) Covalently bound heparin - antithrombin-iii complex, method for its preparation and its use for treating thromboembolism
ATE137965T1 (de) Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE235251T1 (de) Verwendung von amlodipin, eines seiner salze oder felodipin in kombination mit einem ace-hemmer zur herstellung eines arzneimittels zur behandlung von nicht ischämischer kongestiver herzinsuffizienz
DE59600683D1 (de) Verwendung von Trospiumchlorid zur Herstellung eines Arzneimittels zur Behandlung von Blasenkrankheiten
ES8102108A1 (es) Procedimiento para preparar una composicion antitumoral que contiene como ingrediente activo una sal del acido tiazoli- din-4-carboxilico.
ATE8739T1 (de) Pharmazeutische zubereitungen.
IE782515L (en) Treating diarrhoea
ATE77102T1 (de) Verfahren zur reinigung sowie pasteurisierung von urokinase.
ATE227991T1 (de) Verwendung von topotecan in der behandlung von nichtkleinzelligen lungenkarzinomen
JPS5585526A (en) Remedy for allergic disease
JPS5535004A (en) Cell-immunity activator and its preparation
ATE40687T1 (de) Neue pyridinderivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate.
GB1470395A (en) Composition for skin treatment

Legal Events

Date Code Title Description
8364 No opposition during term of opposition